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 Abbreviations 
 
ABC ATP-binding cassette 
ACE angiotensin converting enzyme 
APD-ajmalinium N-(4,4-Azo-n-pentyl)-21-deoxy-ajmalinium 
ATP adenosine triphosphate 
Bamet-R2 antitumoral compound cis-diamine-chloro-cholylglycinate-platinum(II)  
Bamet-UD2 antitumoral compound cis-diamine-bisursodeoxycholate-platinum(II)  
BBB blood-brain barrier 
BCA bicinchoninic acid (protein assay) 
blLPM basolateral liver plasma membranes 
BQ-123 endothelin-A receptor-selective antagonist, a cyclo [D-Trp-D-Asp-Pro-
D-Val-Leu]  
BSP bromosulfophthalein 
CHAPS [3-(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate 
CCK-8 cholecystokinin-octapeptide 
CDCA chenodeoxycholate 
CHO chinese hamster ovary (cell line) 
CMC Critical micelllear concentration 
CNS central nervous system 
Cos-1 CV-1 origin, SV40, transformed African green monkey 
kidney fibroblast cell line 
CRC 220 trivial name of 4-methoxy-2,3,6-trimethylphenylsulfonyl-L-aspartyl-D-
amidinophenylalanine-piperidide 
Cyclo A cyclosporin A 
DDM n-dodecyl-β-D-maltopyranoside 
DHEAS dehydroepiandrosterone sulfate  
DNP-SG [S-(2,4-dinitrophenyl)-glutathione 
DPDPE [D-penicillamine2,5]-enkephalin 
E217βG estradiol-17β-glucuronide 
E3S estrone-3-sulfate 
FOS-16 FOS-choline-16 
GCDCA glycochenodeoxycholic acid 
Gd-B20790 trivial name of gadolonium-18-((3-(2-carboxylbutyl)-2,4,6-
triiodophenyl)amino)-3,6,9-tris(carboxymethyl)-11,18-dioxo-3,6,9,12-
tetrazaoctadecanoic acid 
GSH (reduced) glutathione 
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Abbreviations 
GUDCA glycoursodeoxycholic acid 
HEK human embryonic kidney (cell line) 
HeLa cancerous cervical cell line after Henrietta Lacks who donated the cells 
HepG2 human hepatoma G2 (cell line) 
HMG-CoA hydroxy-3-methyl-glutaryl coenzyme A 
LLCPK Lewis lung carcinoma pig kidney (cell line) 
LTC4 leukotriene C4 
MDCK Madin-Darby canine kidney (epithelial cell line) 
MDR multidrug resistance protein 
MFS major facilitator superfamily 
MOI multiplicity of infection 
MRP multidrug resistance-associated protein 
Na+ sodium 
Ntcp/NTCP Na+/taurocholate cotransporting polypeptide 
OAT organic anion transporter 
Oatp/OATP organic anion transporting polypeptide 
OCT organic cation transporter 
OG n-octyl-β-D-glucopyranoside 
ORF open reading frame 
PBS phosphate buffered saline 
PEPT peptide transporter 
P-gp P-glycoprotein 
PGT prostaglandin transporter 
QSAR quantitative structure-activity relationship 
rT3 reverse triiodothyronine 
Sf9 Spodoptera frugiperda 9 (cell line) 
SLC (O) solute carrier (of Oatps/OATPs) 
SN-38 trivial name of 7-ethyl-10-hydroxycamptothecin 
T3 triiodothyronine 
T4 thyroxine 
TC taurocholic acid 
TCDCA taurochenodeoxycholic acid 
TMH transmembrane α helix 
TUDCA tauroursodeoxycholic acid 
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 Summary 
 
Drug disposition profoundly affects pharmacological effects in tissues and hence 
therapeutic efficacy. Absorption, tissue distribution and elimination of drugs and other 
xenobiotics occur because cellular barriers in an organism are conquerable due to 
the presence of membrane transport proteins. Members of the Organic Anion 
Transporting Polypeptide superfamily (animals: Oatp/Slco, human: OATP/SLCO) 
represent membrane solute carrier proteins. They are responsible for the cellular 
entry of a wide range of endogenous and exogenous amphipathic organic 
compounds. Hence, they allow the passage of drugs across the cellular barriers. 
Oatps/OATPs are found not only in mammals, but also in a big variety of non-
mammalian species, of which many are representatives of animal evolution. No 
proteins with significant homologies have been found in plants, yeast and bacteria. 
This suggests the emergence of an ancient Oatp protein in an early ancestor of the 
animal kingdom. The 36 human, rat and mouse Oatps/OATPs have been divided into 
six families, which are subdivided into subfamilies. The present study focuses on 
members of the OATP1 family, which is a subclass extensively investigated in the 
past. 
Compared to other Oatps/OATPs, which are expressed in multiple tissues, OATP1 
family members exhibit a more restricted expression pattern. The majority of the 
members of the OATP1 family are expressed in the liver, where they are presumably 
involved in the hepatic clearance of albumin-bound compounds from portal blood. 
With reference to the transport mechanism of Oatps/OATPs very little is known. It is 
generally believed that Oatps/OATPs act in a sodium-independent manner and are 
capable to mediate anion exchange. There are several studies reporting a pH-
gradient dependent substrate transport. In terms of protein structure, only theoretical 
approaches have been under consideration. However, there are several conserved 
structural features which are believed to be important for transport function of 
Oatps/OATPs.  
The Na+/bile salt cotransporter Ntcp/NTCP is responsible for sodium-dependent 
hepatocellular uptake of bile salts. Its transport mechanism is well-described, in 
contrary to Oatps/OATPs.  
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The research presented with this PhD thesis includes evolutionary comparisons and 
identification of structural determinants of OATP1 family members. Three aims were 
persued: 1) The functional characterization of the evolutionarily ancient skate 
Oatp1d1 in terms of toxic cyclopeptide uptake compared to mammalian liver 
Oatps/OATPs, 2) the identification of distinct amino acids sequences and/or 
individual amino acid residues essential for Oatp1a4-mediated substrate recognition 
and/or transport and 3) a high-yield expression system for direct solubilization of the 
bile salt cotransporter rat Ntcp was established. After subsequent Ntcp reconstitution 
we aimed at proof of transport function. 
 
In the first part of this work Oatp1d1, expressed in the liver of the little skate 
Leucoraja erinacea, was identified as an uptake system for oligopeptide toxins: high 
affinity uptake for phalloidin (Km ~2.2 µM) and low affinity microcystin uptake (Km 
~27 µM) were determined. The alternative skate liver organic anion transporter, the 
dimeric Ostα/β, exhibited no phalloidin and only minor microcystin transport. Because 
the same toxins are also transported by liver specific Oatps/OATPs in rodents and 
human, the data support the notion that Oatp1d1 represents an evolutionarily ancient 
precursor of mammalian Oatps/OATPs. The closest mammalian OATP orthologue, 
the human brain and testis OATP1C1, did not show any phalloidin transport activity. 
Hence, Oatp1d1 can be closely associated with certain forms of toxic liver injury such 
as for example protein phosphatase inhibition by the water borne toxin microcystin. 
 
In the second part two rat paralogs of 77% amino acids sequence identity, which are 
members of the well-characterized OATP1A subfamily, were investigated. Oatp1a4 is 
a high affinity digoxin transporter while Oatp1a1 does not transport digoxin. Transport 
studies with digoxin in combination with chimeric constructs between the two Oatps 
and point mutations were performed. Consequently, three amino acid residues were 
identified in Oatp1a4, which are essential for transport function. As substrates 
transported by both, Oatp1a4 and Oatp1a1, were affected as well by the three 
Oatp1a4 mutants described, the three amino acids mutated are suggested to be 
important for overall Oatp1a4-mediated transport. It remains unanswered whether 
these three amino acid residues are directly involved in substrate binding or whether 
they affect the 3D structure of the transport protein. 
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The results obtained in the last section are of interest for future isolation of a purified 
organic anion transport protein. In this third part the baculovirus/Sf9 cell-based high-
yield expression system was used for rat Ntcp and Oatp1a1. Functional expression in 
Sf9 cells was proven for both transport proteins. Measured bile salt transport into 
membrane vesicles isolated from Ntcp-expressing Sf9 cells could associated with 
Ntcp. However, transport into membrane vesicles isolated from Oatp1a1-expressing 
Sf9 cells was not diffrent from transport into wildtype Sf9 membrane vesicles. The 
signal could not be associated with the presence of Oatp1a1. Therfore experiments 
were continued with the cotransporter Ntcp. Ntcp Sf9 membrane vesicles were used 
for successful solubilization of functional Ntcp. Prove of Ntcp function was given after 
reconstitution. Na+/taurocholate cotransport with Ntcp in artificial liposomes could be 
determined. For isolation of purified Ntcp at a later date this system will enable 
analyses required to confirm the transport-competent conformation of Ntcp. 
 
Taken together this work has identified: 1) Skate Oatp1d1, an evolutionarily ancient 
precursor of mammalian liver Oatps/OATPs, as a hepatocellular uptake system for 
the toxins phalloidin and microcystin. 2) Three amino acid residues of rat Oatp1a4, 
which are essential for over-all transport function, possibly, they are important for 
substrate recognition or for retaining the protein structure in a transport-competent 
form. And 3) we established an expression system suitable for direct solubilization 
and subsequent functional reconstitution of rat Ntcp. 
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 Zusammenfassung 
 
Pharmakologische Effekte im Gewebe und so die therapeutische Wirkung werden 
stark von der Arzneimittelverteilung beeinflusst. Absorption, Gewebeverteilung und 
Elimination von Arzneimitteln und anderen Xenobiotika finden statt, da Zellbarrieren 
in einem Organismus, dank vorhandenen Membrantransportproteinen, überwindbar 
sind. Mitglieder der Organische Anionen-Transport-Polypeptide (Tiere: Oatp/Slco; 
Mensch OATP/SLCO) vertreten Membrantransportproteine. Sie sind verantwortlich 
für die zelluläre Aufnahme zahlreicher endogener und exogener amphipathischer, 
organischer Verbindungen. Sie ermöglichen folglich die Passage von Azneimitteln 
durch die Zellbarrieren hindurch. Oatps/OATPs finden sich nicht nur in Säugetieren, 
sondern auch in einer grossen Auswahl von Nicht-Säugern, darunter auch manche 
Vertreter der Tierevolution. In Pflanzen, Hefen und Bakterien sind keine Proteine mit 
bedeutender Homologie gefunden worden. Dies lässt vermuten, dass die Entstehung 
eines in Bezug auf die Entwicklung alten Oatps in einem Vorfahre des Tierreiches 
liegt. Die 36 Menschen-, Ratten- und Maus-Oatps/OATPs sind in sechs Familien 
unterteilt, welche wiederum in Unterfamilien eingeteilt sind. Die gegenwärtige 
Untersuchung konzentriert sich auf Mitglieder der OATP1 Familie, eine Unterklasse, 
die in der Vergangenheit umfangreich untersucht worden ist.  
Verglichen mit anderen Oatps/OATPs, die in verschiedenen Geweben exprimiert 
werden, weisen die Mitglieder der OATP1 Familie eine begrenzte Gewebeexpression 
auf. Die meisten Mitglieder der OATP1 Familie sind in der Leber exprimiert, wo sie 
vermutlich für die hepatische Clearance von albumin-gebundenen Verbindungen aus 
dem Portalblut verantwortlich sind. Über den Transportmechanismus der 
Oatps/OATPs ist sehr wenig bekannt. Grundsätzlich wird angenommen, dass 
Oatps/OATPs in natriumabhängiger Weise arbeiten, und dass sie Anionen-
Austausch ermöglichen. Es gibt einige Untersuchungen, die von einer Abhängigkeit 
des Transportes vom pH-Gradienten berichten. In Bezug auf die Proteinstruktur 
stehen nur theoretische Ansätze zur Diskussion. Allerdings wird von einigen 
konservierten strukturellen Eigenschaften angenommen, dass sie für die 
Transporterfunktion von Oatps/OATPs wichtig sind.  
Der Natrium/Gallensalz-Cotransporter Ntcp/NTCP ist verantwortlich für die 
hepatozelluläre Aufnahme von Gallensalzen. Dessen Transportmechanismus ist 
genau beschrieben, im Gegensatz zu den Oatps/OATPs.  
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Die mit dieser Dissertation vorgelegten Forschungsarbeit beinhaltet 
Evolutionsvergleiche und die Identifizierung von Strukturdeterminanten bei 
Mitgliedern der OATP1 Familie. Drei Hauptziele wurden verfolgt: 1) Die funktionelle 
Charakterisierung des in Bezug auf die Entwicklung alten Rochen-Oatp1d1 
betreffend den Transport von toxischen Oligopeptiden, verglichen mit Säugetier 
Leber-Oatps/OATPs, 2) die Identifizierung von genau festgelegten Aminosäure 
Sequenzen und/oder einzelnen Aminosäuren, die für die Substraterkennung 
und/oder den Transport von Oatp1a4 unentbehrlich sind und 3) wurde ein high-yield 
Expressionssystem zur direkten Solubilisierung vom Gallensalz Cotransporter 
Ratten-Ntcp ermittelt. Nach anschliessender Ntcp-Rekonstitution wurde der 
Nachweis für die Transportfunktion erzielt. 
 
Im ersten Teil dieser Arbeit wurde Oatp1d1 - exprimiert in der Leber des kleinen 
Rochen Leucoraja erniacea - als Aufnahmesystem für Oligopeptid-Toxine 
identifiziert: hoch-affiner Phalloidin-Transport (Km ~ 2.2 µM) und niedrig-affiner 
Microcystin-Transport (Km ~ 27µM) wurden nachgewiesen. Der alternative 
Rochenleber-Transporter für organische Anionen, der dimere Ostα/β, weist keinen 
Phalloidin und nur geringfügigen Microcystin Transport auf. Da dieselben Toxine 
ebenfalls von den leberspezifischen Oatps/OATPs in Nagern und Mensch 
transportiert werden, bestärken diese Resultate die Annahme, dass Oatp1d1 ein 
Evolutionsvorläufer der Säugetier-Oatps/OATPs ist. Der nächstverwandte Säugetier-
OATP-Ortholog, der menschliche Hirn- und Testis- OATP1C1, wies keine Phalloidin-
Transportaktivität auf. Oatp1d1 kann also mit einigen Formen der  toxinvermittelten 
Leberschäden in Verbindung gebracht werden, wie zum Beispiel die durch 
Trinkwasser übertragen Protein-Phosphatase-Hemmung mittels Microcystin. 
 
Im zweiten Teil wurden zwei Ratten-Paraloge mit 77% identischen 
Aminosäurensequenzen untersucht, welche Mitglieder der eingehend beschriebenen 
OATP1A Subfamile sind. Oatp1a4 ist ein hoch-affiner Digoxin Transporter, während 
Oatp1a1 kein Digoxin transportiert. Es wurden Transportstudien mit Digoxin in 
Kombination mit chimären Konstrukten zwischen den beiden Oatps und 
Punktmutationen durchgeführt. In Oatp1a4 wurden folglich drei Aminosäuren 
identifiziert, welche für die Transportfunktion unentbehrlich sind. Da Substrate, die
11 
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 von beiden, Oatp1a4 und Oatp1a1, transportiert werden, ebenfalls von den drei 
beschriebenen Oatp1a4-Mutanten beeinflusst worden sind, können die mutierten 
Aminosäuren als wichtig für allumfassenden Oatp1a4 Transport gedeutet werden. Es 
bleibt unbeantwortet, ob die drei Aminosäuren direkt in die Substratbindung involviert 
sind, oder ob sie die 3D Struktur des Transportproteins beeinträchtigen. 
 
Die Resultate des letzten Teils sind von Interesse für eine zukünftige Isolierung eines 
aufgereinigten Organische Anionen-Transporters. In diesem dritten Teil wurde das 
Baculovirus/Sf9 Zellen high-yield Expressionsystem für Ratten-Ntcp und Oatp1a1 
angewendet. Für beide Transportproteine wurde funktionelle Expression in Sf9 
Zellen nachgewiesen. Gallensalztransport in Membranvesikel, welche von Ntcp-
exprimierenden Sf9 Zellen isoliert worden sind, konnte Ntcp zugewiesen werden. 
Transport in Membranvesikel, welche von Oatp1a1-exprimierenden Sf9 Zellen isoliert 
worden sind, war allerdings gleich wie Transport in wildtyp Sf9 Membranvesikeln. 
Das Signal konnte nicht Oatp1a1 zugeordnet werden. Daher wurden Experimente 
mit dem Cotransporter Ntcp weitergeführt. Ntcp Sf9 Membranevesikel wurden für 
eine erfolgreiche Solubilisierung von funktionellem Ntcp eingesetzt. Nach der 
Rekonstitution konnte Ntcp-Funktion nachgewiesen werden. In künstlichen 
Liposomen konnte Natrium/Taurocholat-Cotransport mit Ntcp bestimmt werden. 
Dieses System wird Untersuchungen ermöglichen, die für die Bestätigung der 
transportfähigen Konformation von Ntcp während einer späteren Isolierung von 
aufgereinigtem Ntcp nötig sind. 
 
Zusammenfassend hat diese Arbeit folgendes nachgewiesen: 1) Rochen-Oatp1d1, 
ein Entwicklungsvorläufer von Säugetier Leber-Oatps/OATPs wurde als 
heptozelluläres Aufnahmesystem für die Toxine Phalloidin und Microcystin 
beschrieben. 2) Drei Aminosäuren des Ratten-Oatp1a4 wurden identifiziert, welche 
für die Transportfunktion unentbehrlich sind, die möglicherweise für 
Substraterkennung oder für die Beibehaltung der transportfähigen Proteinstruktur 
wichtig sind. Und 3) haben wir ein Expressionsystem ermittelt, das für die direkte 
Solubilisierung und anschliessende Rekonstitution von Ntcp geeignet ist. 
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C H A P T E R   1 
 
Introduction 
 
 
 1 Introduction 
 
1.1 The role of membrane transport proteins in absorption, tissue-selective 
distribution and elimination of drugs and other xenobiotics 
 
Absorption, tissue distribution and elimination of drugs and xenobiotics exposed to an 
organism can be resumed as drug disposition. Drug disposition profoundly affects 
pharmacological effects in tissues and hence therapeutic efficacy. After oral 
administration, drug disposition starts with absorption into the gut followed by the 
entry into blood-circulation via the portal system. The drug is carried through the 
hepatic portal vein into the liver. Besides being responsible for detoxification, the liver 
eliminates metabolites or unchanged compounds back into the blood circulation or 
via bile into feces. Besides the liver the kidney is the second important organ for 
elimination of drugs and other xenobiotics. Back in the blood circulation, the 
compound may be distributed into tissues and other organs, usually to differing 
extents, where it can exert its pharmacological effect. 
 
The gastrointestinal tract, the liver, the kidney and the blood-brain-barrier (BBB) of 
the central nervous system provide efficient barriers to the permeability of various 
compounds. These cellular barriers are only conquerable due to the presence of 
membrane transport proteins. Comprehensive in vivo and in vitro studies 
demonstrate that membrane transport proteins are not only essential for the selective 
permeability of endogenous compounds, but are also determining factors regarding 
the exposure of an organism to drugs and other xenobiotics. The physicochemical 
properties (size, charge) and/or lipophilicity of a compound determine the molecular 
interaction with the membrane transport protein and therefore the extent of uptake.  
Hence, tissue distribution of drugs is controlled by permeability as a result of 
membrane transport across the cellular barriers mentioned above. At the intestinal 
membrane absorption from the lumen into the portal bloodstream occurs, however 
the membrane transport proteins involved and their exact mode of transport are not 
well defined up to date. Conversely, there are other membrane transport proteins 
responsible for the efflux of xenobiotics from the gut epithelial cells back into the 
gastrointestinal lumen which can be limiting for drug absorption. The liver is reached 
with uptake transport proteins at the basolateral membrane of hepatocytes. There 
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compounds are extracted from the blood and are transported to the metabolizing 
enzymes for biotransformation. This first-pass metabolism is a determinant factor for 
bioavailability of drugs. Later elimination back into the blood circulation or into bile 
occurs with canalicular membrane transporters. In addition to the liver, the kidney is 
the second important organ for drug clearance. Several transport proteins have been 
identified in the renal proximal tubules, which allow the vectorial transport of drugs 
from the blood into to tubular lumen. Reabsorption of substances from the lumen 
back into the renal proximal tubular cells is also sometimes mediated by transporters, 
although many drugs are reabsorbed only by passive diffusion depending on a high 
drug concentration gradient across the renal brush border membrane [1, 2]. Central 
nervous system (CNS) penetration of drugs can be of vital importance when treating 
diseases such as meningitis, seizure disorders and psychiatric illnesses. On the 
other hand, drug transport across the BBB can be unfavorable if the drug causes 
adverse effects after reaching the central nervous system. In general, BBB 
penetration increases with increasing lipophilicity, although some transport proteins 
have been found to facilitate transport of many poorly lipophilic compounds across 
the BBB. BBB penetration of lipophilic drugs can also be unexpectedly poor as a 
result of drug transport efflux proteins found in this region [3].  
 
Inter-individual expression levels of transport proteins can be a determinant factor for 
transport or efflux. Investigations have shown that certain drugs can induce 
expression levels of membrane transport proteins, as well as inhibit the absorption of 
other compounds as they interact with transport proteins at the molecular level [1, 4]. 
So a considerable number of transporter-based clinically important drug-drug 
interactions, associated with polymedication, and drug-food interactions have been 
documented [5]. Understanding of the possible implications of these interaction 
mechanisms and of the consequences of genetic variations should help to provide 
better and safer drug therapy. Accordingly, treatments involving drugs that are 
substrates of the respective transporters could be optimized and individualized. 
15 
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Knowledge concerning drug transport across cell membranes [1, 4, 6, 7] makes it 
evident that there is great interest in having a more detailed understanding of the 
numerous membrane transport proteins at the molecular level. Moreover, malfunction 
of transport across cell membranes is known to cause disorders in different systems 
in an organism, emphasizing the importance of comprehending the working 
mechanisms behind these transport proteins. Therefore, investigations are essential 
not only in basic biomedical research, but also in the applied sciences of future 
therapeutic drug discovery and development using rational drug design. The 
molecular basis of substrate selectivity has to be investigated not only with human 
membrane transport proteins, but also with those found in rodents and other animals 
used in research and development of drugs. Understanding substrate-transport 
protein recognition and binding is a requirement for better assessment of transporter-
mediated drug interaction, emphasizing the clinical relevance of transporter research. 
 
Membrane transport proteins responsible for gastrointestinal, renal, hepatobiliary and 
CNS transport are members of two large protein families: the adenosine-triphosphate 
(ATP)-binding cassette (ABC) transporter superfamily and the solute carrier family of 
proteins. At present, there are 48 known ABC-transporters in humans, including the 
well-investigated P-glycoprotein (P-gp) and multidrug resistance-associated proteins 
(MRPs) [1, 8]. The solute carrier family includes the organic cation transporters 
(OCTs) [9], peptide transporters (PEPTs) [10], organic anion transporters (OATs) [11] 
and organic anion transporting polypeptides (OATPs), which will be the focus of this 
chapter, as well as further characterized in this thesis. These membrane transport 
proteins differ with respect to substrate specificity and mode of transport. However, 
they are all expressed in tissues relevant for disposition of drugs and other 
xenobiotics. Moreover, they transport not only exogenous, but also endogenous 
organic compounds such as bile salts and hormones. In terms of hepatobiliary 
transport, there is overlapping substrate specificity of OATPs (Na+-independent 
hepatocellular uptake) with the sodium-taurocholate cotransporting polypeptide, 
NTCP, (Na+-dependent hepatocellular uptake) for the bile salt taurocholate [12, 13]. 
Overlapping substrate specificity indicates a degree of coordination of transport of 
endogenous compounds between the membrane transporters NTCP and OATPs. 
NTCP will be discussed further at the end of this chapter. 
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1.2 The Organic Anion Transporting Polypeptide (OATP) superfamily  
 
Organic anion transporting polypeptides of the OATP superfamily transmembrane 
solute carriers (denoted OATPs in human and Oatps in all other species; gene 
symbol = SLCO/Slco for solute carrier OATP) are responsible for transport of a wide 
spectrum of amphipathic substrates. In the early 90’s, rat Oatp1a1 was identified by 
expression cloning as the first member of the OATP superfamily, and was shown to 
have properties of a sodium-independent organic anion transporter [14]. 
Subsequently, additional human and rodent members have been discovered. Using 
homology screening either by hybridization experiments or with in silico alignments, 
the availability of genome sequences accelerated the identification of Oatps/OATPs 
even more. To date the superfamily includes 36 human, rat and mouse 
Oatps/OATPs (Fig.1). Further Oatps have been identified in non-mammalian species 
such as chicken, zebra fish, little skate, frog, fruit fly and worm [15-17]. These 
species are representatives of animal evolution implying the presence of an ancestral 
Oatp. However, no proteins with significant homologies have been found in plants, 
yeast or in bacteria [16, 18].  
A new species-independent classification system based on the divergent evolution 
system has been implemented to ease matters (HUGO gene nomenclature 
committee website, www.gene.ucl.ac.uk/nomenclature/) [15]. The overall amino acid 
sequence identity between all Oatp/OATP-related proteins varies between 24% and 
97% [18, 19]. The whole OATP superfamily is classified into six families, which are 
subsequently divided into subfamilies. An individual family contains proteins with 
amino acid sequence identities of ≥ 40% and is indicated by different numbers (e.g. 
OATP1, OATP2, OATP3). Subfamilies contain proteins with amino acid sequence 
identities of ≥ 60% and are denoted by letters (e.g. OATP1A, OATP1B, OATP1C). 
Individual paralogs within a subfamily are indicated by different numbers applied after 
the nominated letter (e.g. Oatp1a1, OATP1A2), while the same end number is 
assigned to orthologs (e.g. OATP1C1 and Oatp1c1) [15]. 
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Fig. 1  
Phylogenetic classification of the OATP superfamily I (A) Phylogenetic classification of human and 
rodent (rat, mouse) members of the OATP/SLCO superfamily. Families contain Oatps/OATPs with 
amino acid sequence identities of more than 40 %; subfamilies contain members with amino acid 
sequence identities of more than 60 %. (B) Enlargement of the evolutionary relationship among 
members of the OATP1 family. The tree was originally calculated using the clustalW program 
(http://www.ebi.ac.uk/clustalw/) and visualized with the program TREEVIEW [20]. 
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Interestingly, there is a well-conserved stretch of 13 amino acids between human, rat 
and mouse Oatps/OATPs. This sequence has been proposed as a so-called 
“superfamily signature” by Hagenbuch and co-workers [18]. Moreover, conserved 
amino acids have been found within the OATP1 and the OATP2 family. Some of 
these residues are also conserved in several other multimember families; however, 
none of them were found to be fully conserved throughout the OATP/SLCO 
superfamily and no “family-specific” residues have been identified so far [16]. 
The evolutionary relationship among Oatps/OATPs is not completely characterized. 
In some families such as OATP3, there is a strict 1:1 relationship between proteins 
found in human, rat and mouse; this is not the case in other families. The subfamily 
OATP1A, for example, has only one human member but five rat members. OATP1B 
contains two human members but only one rat and one mouse member. Such 
inequalities are believed to be a result of gene duplication events after species 
divergence of human and rodents. Not surprisingly, the conservation level is much 
higher within the OATP3 family compared to that of OATP1. There are several 
independent analysis [16, 21, 22] suggesting an evolutionary relationship between 
Oatps/OATPs and the major facilitator superfamily (MFS), which underlie further 
studies leading to a first 3D model of two human OATPs [16]. This aspect will be 
addressed further later in this chapter. 
Because many OATP families, including OATP1 and OATP2, have partially 
overlapping substrate specificities, some active residues are expected to be 
conserved across more than one family. Whether there are evolutionarily conserved 
structural determinants that account for overlapping substrate profiles is unknown. In 
order to bridge the knowledge about the evolutionary relationship and the known 
transport properties of individual Oatps/OATPs, comprehensive investigation is 
needed. 
 
Not all Oatps/OATPs have been functionally well-characterized and very little is 
known about their transport mechanism(s). Moreover, the physiological role(s) of 
most Oatps/OATPs remains unclear and require further investigation. Although some 
members of the OATP superfamily are selectively expressed in the liver at the 
basolateral membrane of hepatocytes, most Oatps/OATPs are present in multiple 
tissues including BBB, choroid plexus, intestine, kidney, placenta, testis, lung and 
heart [18, 23]. 
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The following sections will focus mainly on Oatps/OATPs of the OATP1 family, a 
subclass most often investigated from this superfamily, and on which a particular 
focus will be placed in this thesis. The current knowledge regarding functional 
characteristics, driving force, tissue distribution and structural properties will be 
discussed. 
 
1.2.1 Functional characteristics of OATP1 family members 
As mentioned before, it is well accepted that Oatps/OATPs represent sodium-
independent bile salt and organic anion transporters [14, 24, 25]. Oatp1a1 was 
initially cloned as a sodium-independent bromosulfophthalein (BSP) and taurocholate 
uptake system in rat liver [14, 26]. Later, it could be shown that Oatp1a1 mediated 
transmembrane transport of a wide range of amphipathic organic compounds [27-29]. 
All OATP1A and OATP1B subfamily members show a very broad substrate spectrum, 
in contrast to the OATP1C subfamily with a rather narrow spectrum. However, a 
characteristic found throughout the OATP1 family is the overlapping substrate 
specificity. The amphipathic organic compounds include not only bile salts like 
taurocholate (TC), cholate, glycocholate, taurochenodeoxycholate (TCDCA) and 
tauroursodeoxycholate (TUDCA), but also steroid hormones and their conjugates like 
dehydroepiandrosterone (DHEAS), estrone-3-sulfate (E3S) and estradiol-17β-
glucuronide (E217βG), the thyroid hormones thyroxine (T4), triiodothyronine (T3) and 
reverse triiodothyronine (rT3), as well as eicosanoids like prostaglandins and 
leukotrienes.  
In addition to endogenous substrates, members of the OATP1 family mediate uptake 
of numerous drugs such as the cardiac glycosides digoxin and ouabain, various 3-
hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors like 
pravastatin and rosuvastatin, the antibiotic benzylpenicillin, the angiotensin 
converting enzyme (ACE) inhibitors enalapril and temocaprilat, the chemotherapeutic 
agents methotrexate, the antihistamine fexofenadine, the thrombin inhibitor CRC220, 
the opioid receptor agonist [D-penicillamine2,5]-enkephalin (DPDPE) and deltorphin II 
and even some organic cationic drugs, such as N-methyl quinine and N-methyl 
quinidine. Moreover, OATP1 family members transport toxins such as phalloidin 
(Amanita phalloides), microcystin (cyanobacteria) and ochratoxin A (mycotoxin). 
Table 1 summarizes the substrate specificities for individual rat and human OATP1 
family members with the appropriate publications. Little is known about the mouse 
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OATP1 family members and their individual transport properties, so they have not 
been included. 
Despite their multispecific character, selective compounds have been identified for 
some members of the OATP1 family. For example, gadoxetate and dinitrophenyl-
glutathione (DNP-SG) are transported only by Oatp1a1, cholecystokinin-octapeptide 
(CCK-8), however, is taken up by OATP1B3 and Oatp1b2 and bilirubin plus 
bisglucuronosyl bilirubin are substrates found exclusively for OATP1B1. Differences 
in substrate transport have been documented with respect to apparent affinities, 
namely characterized by the Km value. OATP1C1 is an example of a high affinity T4 
and rT3 transporter (Km  0.09 µM and 0.13 µM, respectively). A second example of 
high affinity transporter is Oatp1a4, which mediates digoxin transport (Km 0.24 µM), 
however the same carrier protein transports BQ-123 with an apparent affinity of 
approximately 600 µM. 
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Table 1 
Substrate specificities of rat and human OATP1 family members, if available expressed with apparent 
affinity Km otherwise with ratios1. 
 
 
Oatp/OATP 
 
Substrate 
 
 
Km [µM] 
 
Expression 
System 
 
Ratio1
 
References 
 
Oatp1a1 
 
b2: 
Taurocholate 
 
 
19-50 
 
 
Oocytes 
CHO cells 
  
 
[14, 27, 28] 
 Cholate 54 Oocytes 
CHO cells 
 [14, 28, 29] 
 Glycocholate 54 Oocytes 
CHO cells 
 [28, 29] 
 TUDCA 13 Oocytes  [29] 
 TCDCA 7 Oocytes 
CHO cells 
 [28, 29] 
 Sulfotaurolithocholate 6 Oocytes  [29] 
 h3: 
Aldosterone 
 
0.015 
 
Oocytes 
  
[39] 
 E217βG 3-20 Oocytes 
CHO cells 
Cos-7 cells 
 [28, 39-41] 
 DHEAS 5 Oocytes 
CHO cells 
 [28, 29] 
 E3S 5-12 Oocytes 
CHO cells 
 [28, 29] 
 Cortisol 13 Oocytes  [39] 
 T4  Oocytes 22.7 [42] 
 rT3  Oocytes 21.3 [42] 
 T3  Oocytes 16.3 [42] 
 e4: 
LTC4
 
0.27 
 
Oocytes 
  
[29, 30] 
 p5: 
CRC 220 
 
30-57 
 
Oocytes 
CHO cells 
  
[28, 43] 
 DPDPE 48 Oocytes  [44] 
 Deltorphin II 137 Oocytes  [44] 
 BQ-123 600 Oocytes  [29] 
 GSH  HeLa cells n.a.9 [45] 
 d6: 
Cerivastatin 
 
6 
 
HEK293 cells 
  
[46] 
 Pravastatin 30 HEK293 cells  [47] 
 Rosuvastatin  HeLa cells 57.0 [48] 
 Fexofenadine 32 HeLa cells  [49] 
 Temocaprilat 47 Cos-7 cells  [40] 
 Enalapril 214 HeLa cells  [50] 
 Ouabain 1700-3000 Oocytes 
CHO cells 
 [28, 39] 
 Gadoxetate 3300 Oocytes  [51] 
 Dexamethasone  Oocytes 2.5 [39] 
 Bamet-R2  CHO cells 6.0 [52] 
 Bamet-UD2  CHO cells 6.0 [52] 
 o7: 
BSP 
 
1-3 
 
Oocytes 
CHO cells 
HeLa cells 
  
[14, 27, 28, 33] 
 DNP-SG 408 Oocytes  [29, 30] 
 APD-ajmalinium  Oocytes 3.0 [53] 
 N-methylquinidine  Oocytes 1.8 [54] 
 Rocuronium  Oocytes 1.7 [54] 
 Monoglucuronosyl bilirubin  Oocytes 2.7 [29] 
 t8 : 
Ochratoxin A 
 
17-29 
 
Oocytes 
CHO cells 
 
  
[28, 55] 
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Table 1 ( continued) 
 
Oatp/OATP 
 
Substrate 
 
Km [µM] 
 
Expression  
System 
 
Ratio 
 
References 
 
OATP1A2 
 
b: 
Taurocholate 
 
 
60 
 
 
Oocytes 
  
 
[24, 56]  
 Cholate 93 Oocytes  [24] 
 TUDCA 19 Oocytes  [24, 53] 
 TCDCA  Oocytes 9.3 [24] 
 Glycocholate  Oocytes 2.8 [24] 
 h: 
DHEAS 
 
7 
 
Oocytes 
  
[56] 
 T3 7 Oocytes  [56, 57] 
 T4 8 Oocytes  [56, 57] 
 E3S 59 Oocytes  [53, 56, 58] 
 E217βG  Oocytes 1.6 [56, 58, 59] 
 rT3  Oocytes 3.1 [57] 
 e: 
Prostaglandin E2
  
Oocytes 
 
4.3 
  
[56] 
 p: 
DPDPE 
 
202 
 
Oocytes 
  
[44, 56] 
 Deltorphin II 330 Oocytes  [44, 56] 
 BQ-123  Oocytes 3.7 [56] 
 CRC 220  Oocytes n.a. [53] 
 
 
d: 
Rosuvastatin 
 
3 
 
HeLa cells 
  
[48] 
 Fexofenadine  6 HeLa cells  [49] 
 Saquinavir 36 HepG2 cells  [60] 
 Unoprostone metabolite 93 Oocytes  [61] 
 Methotrexate 457 Oocytes  [62] 
 Ouabain 5500 Oocytes  [39, 56] 
 Chlorambuciltaurocholate  Oocytes 3.2 [63] 
 Bamet-R2  Oocytes 2.6 [52] 
 Bamet-UD2  Oocytes 3.3 [52] 
 o: 
N-methylquinidine 
 
5 
 
Oocytes 
  
[54] 
 BSP 20 Oocytes  [24, 56] 
 N-methylquinine 26 Oocytes  [54] 
 Recuronium  Oocytes 1.6 [54] 
 APD-ajmalinium  Oocytes 14.9 [39, 53, 54] 
 Unconjugated bilirubin  Oocytes 1.4 [59] 
 Gd-B20790  Oocytes 2.1 [64] 
 t: 
Microcystin-LR 
 
20 
 
Oocytes 
  
[65] 
      
Oatp1a3_v1 
Oatp1a3_v2 
b: 
Taurocholate 
 
10 / 31 
 
Oocytes 
MDCK II cells 
  
[66, 67] 
 h: 
DHEAS 
 
8 / 8 
 
MDCK II cells 
  
[67] 
 E3S 12 / 15 MDCK II cells  [67] 
 T4 20 / 12 MDCK II cells  [67] 
 E217βG 35 / 45 MDCK II cells  [67] 
 T3 44 / 25 MDCK II cells  [67] 
 e: 
Prostaglandin E2
  
Oocytes 
 
n.a. / 1.9 
[66] 
 d: 
Methotrexate 
 
1-2 
 
Oocytes 
MDCK II cells 
LLCPK cells 
  
[66-69] 
 Zidovudine 64 / 76 MDCK II cells  [67] 
 o: 
Folate 
  
Oocytes 
 
1.9 
 
[66, 68] 
 t: 
Ochratoxin A 
 
6 / 17 
 
MDCK II cells 
  
[67] 
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Table 1 (continued) 
 
Oatp/OATP 
 
Substrate 
 
 
Km [µM] 
 
Expression  
System 
 
Ratio 
 
References 
 
Oatp1a4 
 
b: 
Taurocholate 
 
 
35 
 
 
Oocytes 
  
 
[25, 70, 71] 
 Cholate 46 Oocytes  [25] 
 Glycocholate 40 Oocytes  [29] 
 TUDCA 17 Oocytes  [29] 
 TCDCA 12 Oocytes  [29] 
 h: 
E217βG 
 
3 
 
Oocytes 
  
[25, 70] 
 T3 6 Oocytes  [71] 
 T4 7 Oocytes  [70, 71] 
 E3S 11 Oocytes  [25, 70] 
 DHEAS 17 Oocytes  [29, 70] 
 p: 
DPDPE 
 
19 
 
Oocytes 
  
[44, 70] 
 BQ-123 30 Oocytes  [29] 
 Leu-Enkephalin  Oocytes 1.4 [70] 
 d:  
Digoxin 
 
0.24 
 
Oocytes 
  
[25, 70] 
 Atorvastatin 22 HEK293 cells  [72] 
 Pravastatin 38 Oocytes  [73] 
 Cerivastatin  HEK293 cells n.a. [46] 
 Rosuvastatin  HeLa cells 26.0 [48] 
 Biotin  Oocytes 1.7 [70] 
 Ouabain 470 Oocytes  [25] 
 Fexofenadine 6 HeLa cells  [49] 
 o: 
APD-ajmalinium 
  
Oocytes 
 
8.0 
 
[54] 
 Rocuronium  Oocytes 2.6 [54] 
      
Oatp1a5 b: 
Taurocholate 
 
18-30 
 
Oocytes 
COS-1 cells 
  
[34, 71] 
 Cholate 9 COS-1 cells  [34] 
 Glycocholate 15 COS-1 cells  [34] 
 GUDCA 5 COS-1 cells  [34] 
 GCDCA 6 COS-1 cells  [34] 
 Glycodeoxycholate 4 COS-1 cells  [34] 
 Taurodeoxycholate 6 COS-1 cells  [34] 
 TCDCA 7 COS-1 cells  [34] 
 h: 
T4
 
5 
 
Oocytes 
  
[71] 
 T3 7 Oocytes  [71] 
 E217βG 39 Oocytes  [74] 
 DHEAS 162 Oocytes  [74] 
 E3S 268 Oocytes  [74] 
 e: 
Prostaglandin E2
 
35 
 
Oocytes 
  
[74] 
 LTC4  Oocytes n.a. [74] 
 p: 
DPDPE 
 
137 
 
Oocytes 
  
[74] 
 BQ-123 417 Oocytes  [74] 
 d: 
Ouabain 
 
1600 
 
Oocytes 
  
[74] 
 Fexofenadine 58 Oocytes 
HeLa cells 
 
n.a. 
[75, 76] 
 Digoxin  Oocytes n.a. [74] 
 Rosuvastatin  HeLa cells 34.0 [48] 
 o: 
BSP 
 
8 
 
Oocytes 
  
[74] 
      
Oatp1a6 n.a. 
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Table 1 (continued) 
 
Oatp/OATP 
 
 
Substrate 
 
Km [µM] 
 
Expression  
System 
 
Ratio 
 
References 
 
OATP1B1 
 
b: 
Taurocholate 
 
10-34 
 
Oocytes 
HEK293 cells 
  
[56, 71, 77-79] 
 Cholate 11 Oocytes  [56, 64] 
 TUDC 7 HEK293 cells  [80] 
 GUDC 5 HEK293 cells  [80] 
 Glycocholate  Oocytes 3.8 [56] 
 h: 
T3
 
3 
 
Oocytes 
  
[56, 78, 81] 
 T4 3 Oocytes  [56, 78] 
 E217βG 8-10 Oocytes 
HEK293 cells 
 [23, 56, 77-79, 82-84] 
 E3S 0.23-45 Oocytes 
HEK293 cells 
CHO cells 
 [23, 56, 77, 78, 83, 85, 
86] 
 DHEAS 22 Oocytes 
HEK293 cells 
 [56, 77, 78, 81] 
 e: 
Prostaglandin E2
  
Oocytes 
HEK293 cells 
 
4.7- 8.4 
 
[23, 56, 78] 
 LTE4  Oocytes 1.5 [78] 
 LTC4  Oocytes 2.7-16.2 [56, 78] 
 Thromboxane B2  Oocytes 3.8 [78] 
 p: 
DPDPE 
  
Oocytes 
 
3.5 
 
[56, 81] 
 BQ-123  Oocytes 12.0 [56] 
 d: 
Valsartan 
 
1 
 
HEK293 cells 
 
 
 
[87] 
 Olmesartan 43 Oocytes  [88] 
 Pitavastatin 3 HEK293 cells  [84] 
 Rosuvastatin 4-9 Oocytes 
HeLa cells 
 [48, 89, 90] 
 Pravastatin 14-35 Oocytes 
HEK293 cells 
 [47, 79] 
 Cerivastatin  HEK293 cells 
MDCK II cells 
3.1 
n.a. 
[84, 91] 
 Fluvastatin 1.4-3.5 CHO cells  [86, 92] 
 Atorvastatin  HEK293 cells 4 [72] 
 Rifampicin 13 Oocytes  [93] 
      
 Bamet-R2 10 Oocytes  [52] 
 Bamet-UD2 10 Oocytes  [52] 
 Troglitazone sulphate  Oocytes 6.2 [85] 
 Methotrexate  Oocytes 3.0 [81] 
 Benzylpenicilin  HEK293 cells n.a. [23] 
 SN-38  Oocytes 
HEK293 cells 
 1.6 
 n.a. 
[83] 
 Caspofungin  HeLa cells n.a. [94] 
 Bosentan  CHO cells n.a. [95] 
 o: 
Unconjugated bilirubin 
 
0.01 
 
Oocytes 
 [59] 
 Monoglucurosyl bilirubin 0.1 HEK293 cells  [77] 
 BSP 0.1-0.3 Oocytes  
HEK203 cells 
 [56, 77] 
 Bisglucuronosyl bilirubin  
0.3 
 
HEK293 cells 
  
[77] 
 Bilirubin 8.0 Oocytes 
HEK293 cells 
n.a. [59, 77, 93] 
 t: 
Microcystin-LR 
 
7 
 
Oocytes 
  
[65] 
 Phalloidin 17-39 Oocytes 
HEK293 cells 
 [96, 97] 
 Arsenic  HEK293 cells n.a. [98] 
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Table 1 (continued) 
 
Oatp/OATP 
 
Substrate 
 
Km [µM] 
 
Expression  
System 
 
Ratio 
 
References 
 
Oatp1b2 
 
b: 
Taurocholate 
 
 
27 
 
 
Oocytes 
  
 
[99] 
 h : 
DHEAS 
 
5 
 
Oocytes 
  
[74, 99] 
 E217βG 32 Oocytes  [74, 99] 
 E3S 37  Oocytes  [74, 99] 
 T3  Oocytes 1.9 [99] 
 T4  Oocytes 2.3 [99] 
 e: 
LTC4
 
7 
 
Oocytes 
  
[74] 
 Prostaglandin E2 13 Oocytes  [74, 99] 
 p: 
  BQ-123 
 
14 
 
Oocytes 
  
[74] 
 CCK-8 15 Oocytes  [100] 
 DPDPE 22 Oocytes  [74] 
 d: 
Atorvastatin 
 
7 
 
HEK293 cells 
  
[72] 
 Rosuvastain  HeLa cells 39.5 [48] 
 Pravastatin  MDCK II cells n.a. [101] 
 Cerivastatin  HEK293 n.a. [46] 
 o: 
BSP 
 
1 
 
Oocytes 
 
 
 
[99] 
 t : 
Phalloidin 
 
6 
 
Oocytes 
     
[96] 
 Microcystin  Oocytes 2.3 [65] 
      
OATP1B3 b: 
Taurocholate 
 
6-42 
 
Oocytes 
  
[36, 56, 81] 
 Glycocholate 43 Oocytes 3.3 [36, 56] 
 Cholate 42 Oocytes  [36] 
 TUDC 16 HEK293 cells  [80] 
 GUDC 25 HEK293 cells  [80] 
 TDCA  Oocytes 1.9 [36] 
 TCDCA  Oocytes 1.8 [36] 
 h: 
E217βG 
 
5 
 
Oocytes 
HEK293 cells 
 
 
7.4 
 
[56, 77, 102] 
 T3 6 Oocytes  [56, 81] 
 DHEAS  Oocytes 
HEK293 cells 
7.1 
5.2 
[56, 102] 
 T4  Oocytes 1.7 [56] 
 E-3-S  Oocytes 2.3 [56] 
 e: 
LTC4
  
Oocytes 
HEK293 cells 
 
2.3 
2.3 
 
[56, 102] 
 p: 
CCK-8 
 
11 
4 
 
Oocytes 
HEK293 cells 
  
[56, 84, 100] 
 GSH 4651 Oocytes  [36] 
 Deltorphin II  Oocytes 1.4 [56] 
 BQ-123  Oocytes 12.0 [56] 
 DPDPE  Oocytes 10.3 [56] 
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Table 1 (continued) 
 
Oatp/OATP 
 
Substrate 
 
Km [µM] 
 
Expression  
System 
 
Ratio 
 
References 
 
OATP1B3 
(continued) 
 
d: 
Telmisartan 
 
 
1 
 
 
HEK293 cells 
  
 
[103] 
 Olmesartan 72 Oocytes  [88] 
 Rifampicin 2 Oocytes  [93, 104] 
 Pitavastatin 3 HEK293 cells  [84] 
 Paclitaxel 7 Oocytes  [105] 
 Valsartan 18 HEK293 cells  [87] 
 Methotrexate 25 Oocytes  [81] 
 Rosuvastatin  HeLa cells 4.5 [48] 
 Ouabain  Oocytes 5.9 [56] 
 Digoxin  Oocytes 2.4 [56] 
 Fexofenadine 108 HEK293 cells  [106, 107] 
 Bosentan  CHO cells n.a. [95] 
 o: 
Unconjugated bilirubin 
 
0. 039 
 
Oocytes 
  
[59] 
 BSP 0.3-3 Oocytes 
HEK293 cells 
 [56, 77, 102] 
 Monoglucuronosyl bilirubin 0.5 HEK293 cells  [77] 
 t: 
Amanitin 
 
4 
 
MDCK II cells 
  
[108] 
 Phalloidin 8 Oocytes  [96] 
 Microcystin-LR 9 Oocytes  [65] 
Oatp1c1 h: 
T4
 
0.2 
 
HEK293 cells 
  
[109] 
 E217βG 10 HEK293 cells  [109] 
 E3S  HEK293 cells 1.7 [109] 
 rT3  HEK293 cells 19.7 [109] 
 d: 
Cerivastatin 
 
1 
 
HEK293 cells 
  
[109] 
 Pravastatin  HEK293 cells 1.6 [109] 
 t: 
Ochratoxin A 
  
HEK293 cells 
 
1.5 
 
[109] 
      
OATP1C1 h: 
T4
 
0.09 
 
Oocytes 
CHO cells 
 
 
10.8 
 
[110] 
 rT3 0.13 CHO cells  [110] 
 T3  CHO cells 1.7 [110] 
 E3S  CHO cells 1.8 [110] 
 E217βG  CHO cells 2.3 [110] 
 o : 
BSP 
 
 
 
Oocytes 
CHO cells 
 
2.1 
2.3 
 
[110] 
1Ratios correspond to uptake of Oatp/OATP cRNA injected oocytes or transfected cells devided by uptake 
  in control oocytes or cells, respectively. 
 
2b: bile salts, 3h: hormones, 4e: eicosanoids, 5p: peptides, 6d: drugs, 7o: other organic ions, 8t: toxins 
9n.a.: not available 
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1.2.2 Driving force(s) investigated with OATP1 family members 
In spite of the important and rapid advances made in understanding individual 
transport properties of members of the OATP1 family, the mechanisms involved in 
the functional regulation under normal and pathological circumstances, namely the 
driving force of these membrane transport proteins, are poorly understood. 
Oatp/OATP-mediated transport is agreed on at large to be independent of sodium, 
chloride and potassium gradients, membrane potential and ATP-levels and is 
generally believed to occur by electroneutral exchange, in which the cell uptake of 
organic anions is coupled to the efflux of anions such as HCO3-, GSH and/or 
glutathione-S-conjugates [14, 24, 25, 30-34].  
Satlin and co-workers have suggested electroneutral and pH-dependent anion 
exchange studying Oatp1a1-mediated transport. Studies with HeLa cells expressing 
Oatp1a1 proposed HCO3¯ to be exported in exchange for taurocholate; uptake of this 
bile salt was accelerated by coupling an outwardly directed pH-gradient with extra 
cellular taurocholate-stimulated HCO3¯ extrusion, this in alkali-loaded cells [32]. The 
other solute GSH has been reported to function as an intracellular substrate for 
Oatp1a1 as well as for Oatp1a4. In oocytes expressing Oatp1a1, a 1:1 stoichiometric 
GSH/taurocholate exchange was shown [30]. Similar studies with Oatp1a4 could not 
prove Oatp1a4 as a GSH exchanger, but rather suggested Oatp1a4 as a primary 
export carrier. These observations indicate that an outwardly directed GSH 
electrochemical gradient can be described as a driving force only for Oatp1a1 [31]. 
Human OATPs that have thus far been examined for their ability to transport GSH 
are OATP2B1, OAT1B1 and OATP1B3 [35-37]. A recent study focused mainly on 
OATP1B1 and OATP1B3 and reported, amongst others, new findings regarding the 
transport mode [36]. OATP1B1 was found to behave similarly to what has been 
shown for Oatp1a1. In the studies of Briz et al OATP1B1 behaves as a GSH/organic 
anion exchanger and is involved in uptake processes. The published results 
concerning GSH transport by OATP1B3 are controversial. Ballatori and co-workers 
[35, 37] showed up to date with two studies that GSH is not required for transport 
activity, i.e. has no effect on uptake nor on efflux with OATP1B1 and OATP1B3. 
However, the group of Briz and co-workers [36] found that OATP1B3 appeared to 
accept GSH as a low affinity substrate. The notion was made that OATP1B3 
mediates extrusion of organic anions by symporting with GSH. The most probable 
stoichiometry found for this cotransport of GSH and bile acids was 2:1. Consequently, 
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the transport mechanism of OATP1B1 and OATP1B3 were not described being the 
same, as it has been demonstrated for Oatp1a1 and Oatp1a4. GSH is synthesized in 
every mammalian cell and is essential for a multitude of biochemical processes. 
There are several members of the multidrug resistance-associated protein family of 
ABC transporters, which have also been found to be responsible for GSH transport, 
indicating a wide range of export mechanisms for endogenous GSH [35].  
Further studies have focused on a pH-sensitivity reported to be responsible for 
functional regulation of Oatps/OATPs. Intracellular acidification in CHO and HepG2 
cells affected glycocholate uptake mediated by Oatp1a1. It was concluded that low 
intracellular pH might modify the driving forces or that the protonation of the 
intracellular domain of the membrane protein might trigger the changes observed [38].  
Taken together, the driving force(s) of Oatps/OATPs is far from being well 
understood. Nevertheless, the pH sensitivity of Oatps/OATPs appears to be an 
important factor that needs to be pursued further. 
 
1.2.3 Tissue distribution of OATP1 family members 
For some, but not all Oatps/OATPs, tissue distribution has been studied using 
different techniques (e.g. Northern and Western blots and immunohistochemistry). 
Consistent with their potential role in detoxification processes, Oatps/OATPs are 
present in various tissues such as the BBB, choroid plexus, intestine, liver, kidney, 
testis, placenta, lung and heart [15]. Members of the OATP1 family show a more 
restricted tissue expression pattern, compared to Oatps/OATPs from other families, 
which can be detected in almost every tissue that has been investigated [15]. This 
indicates that certain Oatps/OATPs have organ-specific functions, while others might 
be involved in house-keeping functions. Tissue distribution at protein level published 
so far for members of the OATP1 family is summarized in Table 2. 
The subfamily OATP1A comprises 1 single human member, namely OATP1A2 (Fig. 
1, Table 2). OATP1A2 was originally cloned from a human liver cDNA library, but its 
strongest expression is in the brain [24]. In addition, OATP1A2 could be localized in 
the kidney [111] and ciliary body epithelium of the eye [61]. Further studies showed 
expression in liver and colon cancer cells, as well as in a human hepatoma cell line 
[23, 47, 102]. OATP1A2 has 5 rat (i.e. Oatp1a1, Oatp1a3, Oatp1a4, Oatp1a5 and 
Oatp1a6) and 4 mouse (i.e. Oatp1a1, Oatp1a4, Oatp1a5 and Oatp1a6) homologues 
within the subfamily (Figure 2). Except for Oatp1a6, which so far seems to be an 
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orphan transporter, all members of the OATP1A-subfamily have been characterized 
thoroughly regarding their expression profile, as documented in Table 2. 
The subfamily OATP1B has two human members OATP1B1 and OATP1B3, which 
share a similar expression pattern with the paralogue Oatp1b2 (Fig. 1, Table 2). 
OATP1B1 was cloned from human liver [23, 47, 78, 102]. Localization of OATP1B1 
appears restricted to the basolateral plasma membrane of hepatocytes [23, 47, 78, 
102]. Its apparent exclusive expression in human liver suggests that OATP1B1 plays 
a crucial role in the hepatic clearance of albumin-bound amphipathic organic 
compounds, including drugs. In addition, OATP1B3 was cloned from human liver [81, 
102]. Under normal physiological conditions, OATP1B3 is predominantly expressed 
at the basolateral plasma membrane of hepatocytes [81, 102]. Even though 
OATP1B3 was first thought to be a selective liver carrier, expanded studies showed 
expression in various human cancer tissues, as well as in different tumor cell lines 
derived from gastric, colon, pancreas, gallbladder, lung and brain cancers [81]. The 
pathobiological significance of OATP1B3 present in human cancer tissues remains to 
be investigated. For the two human OATP1B subfamily members in rat the single 
orthologue Oatp1b2 has been identified. Oatp1b2 is mainly expressed in the liver [74], 
but also found in the ciliary body epithelium of the eye [61]. 
The subfamily OATP1C contains human OATP1C1, which has been isolated from a 
human brain library [110]. OATP1C1 differs from most other OATP superfamily 
members, because of its selective distribution in brain and testis. In testis, OATP1C1 
localizes to sterogenic Leydig cells [110]. The rat orthologue Oatp1c1 has been 
isolated from a cDNA library enriched in mRNAs specific to the BBB [112]. 
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Table 2 
Tissue distribution of human and rat members of the OATP1 family determined at protein 
level by Western blotting and immunohistochemical analysis  
Oatp/OATP Length  
(amino acids) 
Tissue distribution and 
cellular/subcellular 
Expression 
References 
Oatp1a1 670 Liver (bl1) 
Kidney (proximal tubules, ap2) 
Choroid plexus (ap) 
[28, 29, 113-116] 
OATP1A2 670 Liver (bl) 
Brain (frontal cortex) 
Eye (ciliary body) 
[44, 53, 61] 
Oatp1a3_v1 
Oatp1a3_v2 
669 Kidney (proximal tubules, bl) [66, 68, 69] 
Oatp1a4  661 Liver (bl) 
Brain (BBB) 
Choroid plexus (bl) 
Eye (ciliary body, retina) 
[29, 44, 70, 115, 117] 
Oatp1a5 670 Jejunum 
Choroid plexus 
[34, 118] 
Oatp1a6 670 n.a.3  
OATP1B1 691 Liver (bl) [78, 102, 119] 
Oatp1b2 687 Liver (bl) 
Eye (ciliary body) 
[61, 74] 
OATP1B3 702 Liver (bl) 
Cancer cell lines 
[81, 102] 
Oatp1c1 716 Brain [112] 
OATP1C1 712 Brain 
Eye (ciliary body) 
Testis (Leydig cells) 
[61, 110] 
1 bl : basolateral 
2 ap: apical 
3 n.a.: not available 
 
 
1.2.4 Structural properties of OATP1 family members 
In order to understand drug transport and for design of drugs with optimized 
biodistribution and elimination, it is important to elucidate the structure of the 
substrate binding regions of the SLCO superfamily multispecific transporters. There 
is also a great interest from the biomedical perspective in comprehending how 
various substrates bind to these regions, whether more than one substrate can bind 
simultaneously and how substrate binding initiates the translocation process. Finally, 
these questions can only be solved by crystallization of ligand-transporter complexes, 
in combination with functional characterization of critical residue point mutations. 
Accordingly, many studies have contributed to certain knowledge about the structural 
properties of Oatps/OATPs which can be applied to OATP1 family members. 
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Members of the OATP superfamily identified so far consist of 643 (Oatp2A1) to 848 
(OATP5A1) amino acids [18] with molecular masses of 60 to 90 kDa. Several 
conserved structural features are believed to be important for the transport function 
of Oatps/OATPs. These features include the number of transmembrane-spanning α 
helices (TMH), the large extra cellular region between TMH 9 and 10 and the so-
called “superfamily signature” with the consensus sequence D-X-RW-(I,V)-GAWW-X-
G-(F,L)-L [18] (Fig. 2B). According to hydropathy analysis, all Oatps/OATPs are 
thought to have 12 TMHs [18, 23, 24], with their C- and N-termini localized at the 
intracellular side (Fig. 2A). However, it has not yet been proven experimentally for 
any Oatp/OATP and very little is known about the arrangement of the TMHs relative 
to each other. The large extra cellular region features many conserved cysteines and 
resembles the zinc finger domains of DNA binding proteins [120]. Moreover, there 
are N-glycosylation sites in common among Oatps/OATPs in the extra cellular loop 2 
and 5 (Fig.2A).[14]  
 
 
 
Fig. 2 
Predicted 12 transmembrane helices model of rat Oatp1a1 (A) and enlargement of the OATP 
superfamily signature (B) I Within the theoretical Oatp1a1-model conserved amino acids are 
indicated in black. Conserved and charged amino acids are given in grey and conserved Cysteins are 
marked in green. Potential N-glycosilation sites (Y) are present on extra cellular loops (adapted from 
[18] ). 
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Recent investigations aiming at the elucidation of the structure-function relationship 
of the cysteine-rich extra cellular loop yielded results with an OATP2 family member, 
which may also apply to Oatps/OATPs from the OATP1 family.  Firstly, truncated 
OATP2B1 lacking this large extra cellular loop showed intracellular accumulation of 
the protein, indicating the importance of this loop for surface expression. The studies 
were extended by investigating the effects of mutations of 10 conserved extra cellular 
cysteines to alanines. It could be shown that the cysteines were necessary for 
targeting of OATP2B1 to the cell surface and that the majority of the 10 mutants 
impair transport function. Furthermore, all 10 extra cellular cysteines are likely to be 
involved in disulfide linkage. In conclusion, several indices exist that the cysteines 
are essential for a mature protein and therefore for proper cell surface expression 
[121].  
The distant relationship of Oatps/OATPs with the major facilitator superfamily (MFS) 
of transport proteins, of which almost all members feature also 12 TMHs [22], 
underlies a study [16] in which bioinformatic tools helped to identify 2 MFS transport 
proteins with significant sequence structure homology to Oatps/OATPs. Both proteins 
feature a single substrate-binding site and operate by an alternating-access 
mechanism through a rocker-switch type of movement. They were initially used as 
templates for modeling a 3D model of two human OATPs. The results include a 
noteworthy theoretical model of an OATP1 family member, namely OATP1B3 (Fig. 
3A), as well as of OATP2B1. Analysis of the conservation pattern identified the 
presence of a central pseudo twofold symmetry axis, perpendicular to the membrane 
plane, and a central pore that might be functionally significant. Measuring the 
electrostatic potential on the surface of the protein showed that the putative pore was 
positive. This is consistent with a pore that is exposed to the aqueous phase and 
binding and transporting negatively charged compounds. This conforms also to the 
anionic nature of the majority of Oatp/OATP substrates (Fig. 3B). Additionally, the 
pore was large enough to accommodate typical Oatp/OATP substrates. The lateral 
side of the model was shown to be neutral, as it is required for its interposition with 
the lipid bilayer.  
33 
Introduction 
 
Fig. 3 
Cartoon representation of the theoretical structural model of OATP1B3 I Transmembrane helices 
of the OATP1B3 structural model [16] are shown in colors. The approximate positions of the 
membrane bilayer and the N- and C- termini are indicated (A). OATP1B3 substrate digoxin (shown in 
cyan as stick model) was fitted into the pore, viewed from the intracellular side. The docking was 
performed by GOLD [122]. The figure was generated by PyMOL (www.pymol.org). 
 
 
Other conserved features of Oatps/OATPs are the amino acids, which are 
preferentially in TMH 2 to 6, in the extra cellular loops 1, 3, 5 and in the intracellular 
loops 1, 2, 4 und 5 [18]. The study of Meier-Abt and co-workers [16] confirmed that 
the conserved amino acid residues within the OATP1 and OATP2 family may 
characterize their function. In the 3D models, they were predicted to be solvent-
exposed and facing the pore, which would therefore be responsible for the positive 
potential of the pore, or they were predicted to play a key role in stabilizing the α 
helices. Surprisingly, a structure-based alignment of the large extra cellular region 
model showed no positive electrostatic potential. This indicates that this region is 
probably not involved in the attraction of the substrate to the transporters. It can be 
speculated that the large extra cellular region may cover the pore in the absence of a 
substrate, moving away upon substrate binding.  While this in silico work is a 
theoretical study, it so far remains the most advanced investigation of structural 
properties of Oatps/OATPs. 
Extended functional studies on OATP1B1 brought up an unexpected characteristic of 
the membrane transport protein. OATP1B1-mediated concentration dependent 
transport of estrone-3-sulfate was characterized by biphasic kinetics using 
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transfected HEK293 cells [123]. Confirmation was given by using a different 
expression system, Xenopus laevis oocytes. Km values were found for a high- and a 
low-affinity component of estrone-3-sulfate. Accordingly, the studies revealed that 
two functional sites were apparently involved on one single OATP transporter. 
Recent work could reassure this finding of multiple substrate binding for estrone-3-
sulfate on OATP1B1 [86]. 
The broad substrate specificity of many Oatps/OATPs raises the question as to the 
common chemical and/or structural denominators of Oatp/OATP substrates. It can 
very well be that certain common features determine the molecular basis of the 
multispecificity of Oatps/OATPs. Two research groups worked with different 
approaches to generate pharmacophore models in order to understand the structural 
requirements of Oatps/OATPs. The group of Yarim et al based their model on 
knowledge concerning Oatp1a5 [124], which has a broad substrate specificity and is 
well investigated regarding transport properties. Apparent affinity (Km) values of 
Oatp1a5 substrates were used to perform 2D/3D-quantitative structure-activity 
relationships (QSAR) to yield a predictive description of global structural 
requirements for interaction between the substrates and Oatp1a5. The ligand-based 
approach was extrapolated for known Oatp/OATP substrates. This hypothetical 
pharmacophore model comprises the following topological information on the 
substrate binding site: firstly, a negatively charged group, secondly, a relatively 
extended hydrophobic region and thirdly, a hydrogen bond donor (Fig. 4).  
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Fig. 4 
Hypothetical pharmacophore features exemplified by taurocholate I (adapted from [124]) 
 
 
Within the second study aiming at the elucidation of the molecular mechanisms of 
multispecificity, Chang and co-workers performed a combination of pharmacophore 
building and meta-analysis [125]. The meta-analysis was based on literature data on 
two extensively studied OATP1 family members, rat Oatp1a1 and human OATP1B1. 
From these combined datasets a meta-pharmacophore was generated, speculating 
on the essential features responsible for recognition at the membrane transport 
protein and enabling transport across the plasma membrane. The pharmacophore 
models for Oatp1a1 and OATP1B1 consist of 2 hydrogen acceptors and 2 or 3 
hydrophobic features. Both studies have one key feature of their generated 
pharmacophores in common, namely the hydrophobic bulky and relatively extended 
region. Additionally, Yarim et al found a negatively charged group. Considering 
hydrogen bond donors or acceptors, the two research groups remain in discordance. 
 
Altogether, a reasonable amount of work has been achieved towards the elucidation 
of structure-function relationship of Oatps/OATPs. The knowledge regarding some 
important physiological roles stimulates ongoing investigation and will hopefully 
climax in the crystallization of an Oatp/OATP. 
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1.3 The bile acid transporter Na+/taurocholate cotransporting polypeptide 
(Ntcp/NTCP) 
 
As mentioned before, not only xenobiotics are transported into the liver but also 
many endogenous compounds important for intact liver physiology and metabolism. 
Endogenous compounds like conjugated and unconjugated bile acids are 
translocated across the basolateral membrane into hepatocytes. This uptake of bile 
acids is mediated mainly by sodium-dependent cotransport. In addition, several 
members of the OATP superfamily mediate sodium-independent bile acid/organic 
anion exchange. Bile acids are the predominant organic solutes in bile and are 
subject to the enterohepatic circulation. Bile formation itself is essential for normal 
intestinal and lipid digestions and absorption, cholesterol homeostasis and for 
hepatic excretion of lipid-soluble drugs, xenobiotics and heavy metals. Bile acids are 
thus found in a continuous flow which is restricted to hepatocytes, the biliary tree, the 
intestine and the portal blood [126]. Accordingly, the enterohepatic circulation is 
dependent on several transport systems, among which the two sodium-dependent 
bile acid cotransporters of the SLC10 family play a crucial role. Na+/taurocholate 
cotransporting polypeptide located at the basolateral membrane of hepatocytes is in 
charge of extracting bile acids efficiently from the portal blood for resecretion across 
the canalicular membrane into the bile. In parallel the apical sodium-dependent bile 
salt transporter (ASBT) expressed in ileocytes, actively removes bile acid from the 
intestinal lumen and allows their return to the liver via the portal circulation [13, 127].  
 
1.3.1 Functional characteristics and expression pattern of Ntcp/NTCP 
Ntcp/NTCP (animals: Ntcp; human: NTCP) belongs to the sodium bile salt 
cotransport family SLC10. Rat Ntcp was isolated first by expression cloning using the 
Xenopus laevis expression system [128]. Subsequently further orthologs were 
identified in human [129], mouse [130] and rabbit [131]. 
As pointed out, Ntcp/NTCP represents the predominant uptake system for 
conjugated and unconjugated bile acids in hepatocytes. Substrate specificity 
summarized in [12, 132] comprises cholate, taurocholate (Km 6-34µM), glycocholate 
(Km 27µM), taurochenodeoxy cholate (Km 5µM), taurodeoxycholate (Km 14µM) 
taurohydroxycholate (Km 7µM), tauromurocholate and the bile salt sulfate 
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chenodeoxycholate-3-sulfate. Non-bile salt substrates identified so far are estrone-3-
sulfate (Km 27-60µM), DHEAS, BSP (Km 4µM) and drugs covalently bound to 
taurocholate (e.g. chlorambucil). Up to date no drug has been described being 
mediated by Ntcp. Overlapping substrate specificity with OATP1 family members 
also found at the basolateral membranes of hepatocytes is evident when comparing 
with substrates mentioned in Table 1. 
The driving force for Ntcp/NTCP is provided by the inwardly directed electrochemical 
Na+-gradient maintained by the basoateral Na+/K+-ATPase as well as the negative 
intracellular potential. Detailed analysis have revealed that transport is electrogenic 
with a Na+: taurocholate stoichometry of at least 2:1 [133, 134]. 
More recently, expression of rat Ntcp was also detected in the luminal membranes of 
pancreatic acinar cells [135]. This is a counter evidence for Ntcp/NTCP representing 
a liver-specific expressed membrane transport polypeptide as assumed for a long 
time. 
 
1.3.2 Structural properties of Ntcp/NTCP 
Currently there is only limited information about the structural properties of 
Ntcp/NTCP as disclosed before also for Oatps/OATPs. Rat/mouse and human 
Ntcp/NTCP consist of 362 and 349 amino acids, respectively. They show an overall 
sequence identity of > 73% and 5 possible N-linked glycosilation sites have been 
suggested [128]. Molecular mass determinations of native rat Ntcp in isolated 
basolateral liver plasma membranes (blLPM) showed an apparent molecular mass of 
51 ± 3 kD (mean ± SD). Deglycosilation experiments decreased the apparent 
molecular mass from 51 to 33.5 kD, which demonstrates that native Ntcp is 
extensively glycosilated in intact rat hepatocytes. This was suggested also because 
of a consistent broad band for Ntcp in blLPM with Western blot analysis [136]. 
The ligand-binding sites have not been localized and the exact transport mechanism 
remains unknown. Bioinformatic predictions and experimental evidence have shown 
that Ntcp/NTCP has an external N-terminus, an odd number of TMHs (7 or 9) and a 
cytoplasmic C-terminus [137, 138]. Ultimately, an approach such as X-ray 
crystallography will be required to determine topology. 
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Aims of the Presented Work 
 
 
CHAPTER 2 I Aims of the Presented Work 
As mentioned before, investigations on substrate specificity of individual members of 
the OATP superfamily have been extensive. In terms of structure-function 
relationship, specific structural determinants required for Oatp/OATP transport 
activity have not been specified yet. 
The current work focuses on members of the well-investigated OATP1 family. The 
first aim was to examine whether an evolutionarily ancient Oatp, namely Oatp1d1 
from skate liver, shares the transport properties with the more evolved mammalian 
liver Oatps/OATPs. This was examined with transport studies using the toxins 
phalloidin and microcystin as substrates. The second aim was to identify distinct 
amino acid sequences and/or individual amino acid residues that are essential for 
substrate binding and/or transport of rat Oatp1a4. Because Oatp1a4 is a digoxin-
transporter and Oatp1a1 does not transport digoxin, the cardiac glycoside was used 
as a model substrate. Transport studies were performed with chimeric constructs and 
mutated Oatp1a4.  
Investigations towards complete molecular description of specific structural 
properties and future purification of an organic anion transporter require a solubilized 
and isolated membrane transport protein. The third aim was to establish a high-yield 
expression system for functional characterization and functional reconstitution of 
organic anion transporters. For this purpose the baculovirus/Sf9 cell-based 
expression system was used. 
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CHAPTER 3 I Abstract 
3. 1 Abstract 
Organic anion transporting polypeptides (animals: Oatps; human: OATPs) mediate 
cellular uptake of numerous organic compounds including xenobiotic toxins into 
mammalian hepatocytes. In the little skate Leucoraja erinacea a liver specific Oatp 
(Oatp1d1, also called sOatp) has been identified and suggested to represent an 
evolutionarily ancient precursor of the mammalian liver OATP1B1 (human), Oatp1b2 
(rat), and OATP1B3 (human). The present study tested whether Oatp1d1 shares 
functional transport activity of the xenobiotic oligopeptide toxins phalloidin and 
microcystin with the mammalian liver Oatps/OATPs. The phalloidin analogue [3H]-
demethylphalloin was taken up into skate hepatocytes with high affinity (Km ~ 0.4 
µM), and uptake could be inhibited by phalloidin and a variety of typical Oatp/OATP 
substrates such as bromosulfophthalein, bile salts, estrone-3-sulfate, cyclosporine A 
and high concentrations of microcystin-LR (Ki ~ 150 µM). When expressed in 
Xenopus laevis oocytes Oatp1d1 increased uptake of (Km ~ 2.2 µM) and 
microcystin-LR (Km ~ 27 µM) 2 to 3-fold over water-injected oocytes, whereas the 
alternative skate liver organic anion transporter, the dimeric Ostα/β, exhibited no 
phalloidin and only minor microcystin-LR transport. Also, the closest mammalian 
Oatp1d1 orthologue, the human brain and testis OATP1C1, did not show any 
phalloidin transport activity. These results demonstrate that the evolutionarily ancient 
Oatp1d1 is able to mediate uptake of cyclic oligopeptide toxins into skate liver. These 
findings support the notion that Oatp1d1 is a precursor of the liver specific 
mammalian Oatps/OATPs and that its transport properties are closely associated 
with certain forms of toxic liver injury such as for example protein phosphatase 
inhibition by the water borne toxin microcystin. 
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3. 2 Introduction 
Organic anion transporting polypeptides (animals: Oatps; human: OATPs) of the 
OATP/SLCO superfamily of solute carriers mediate multispecific substrate uptake in 
various organs of vertebrate animal species [1]. In mammalian liver, members of the 
OATP1 family (i.e. mouse and rat liver: Oatp1a1, Oatp1a4, Oatp1b2; human liver: 
OATP1A2, OATP1B1, OATP1B3) mediate sodium-independent uptake of bile salts, 
organic dyes (e.g. bromosulfophthalein), steroids and steroid conjugates, thyroid 
hormones, prostaglandins, various oligopeptides and numerous drugs [2]. 
Interestingly, the substrate spectrum of the hepatic Oatps/OATPs also include 
endogenous and exogenous linear and cyclic oligopeptides such as the endothelin 
receptor antagonist BQ-123, the thrombin inhibitor CRC220, the opioid receptor 
agonists DPDPE and deltorphin II and the enterohepatic hormone cholecystokinin 8 
(CCK) [1, 2]. More recently, the hepatic Oatps/OATPs have also been shown to be 
responsible for the uptake of the hepatotoxic exogenous cyclic peptides phalloidin, α-
amanitin and microcystin into rat and/or human livers [3-5]. These findings explain 
the observations of prevention of amatoxin and microcystin induced liver injury by 
concomitant administration of typical Oatp substrates [6, 7]. 
In the liver of the little skate Leucoraja erinacea an evolutionarily ancient Oatp has 
been identified at the basolateral (sinusoidal) plasma membrane domain of 
hepatocytes [8]. This sOatp or Oatp1d1/Slco1d1 (for classification and nomenclature 
see [1] ) shares 41.2-43.3% amino acid sequence identities with the rat liver Oatp1b2 
(also called Oatp4) and the human liver OATP1B1 (also called OATP-C, OATP2, 
LST-1) and OATP1B3 (also called OATP8) [8]. Furthermore, Oatp1d1 exerts the 
highest degree of homology (50.4% amino acid sequence identity) with the most 
ancient OATP1 family member, i.e. OATP1C1 (or OATP-F) [1, 9]. Because the 
mammalian liver Oatps/OATPs have most probably arisen from gene duplication 
after species divergence [1, 2], it was of interest to examine whether the ancient 
skate Oatp1d1 shares the phalloidin and microcystin transport properties with the 
mammalian liver Oatps/OATPs. For this purpose, transport of radioactively labelled 
phalloidin was measured in isolated skate hepatocytes, and its transport was 
characterized by kinetic and inhibition studies. Furthermore, Oatp1d1 was expressed 
in Xenopus laevis oocytes in order to elucidate its suggested transport functions for 
phalloidin and the water-borne hepatotoxin microcystin. 
49 
CHAPTER 3 I Material and Methods 
3. 3  Material and Methods 
Animals I Male skates (~ 1 kg) were caught by net in Frenchman’s Bay off of Bar 
Harbor, ME, USA. They were maintained in large aerated tanks supplied with 
continuously flowing 15°C seawater and were used within 1-3 days of capture. 
Animals were anesthetized prior to hepatectomy with sodium pentobarbital (2.5 
mg/kg) injected via a caudal vein. Female Xenopus laevis were purchased from 
Xenopus I, Inc., (Dexter, MI, USA) and from the African Xenopus facility c.c., 
Noordoek, South Africa.  The frogs were maintained and treated according to NIH 
guidelines. 
 
Materials I Radiolabeled [3H]-taurocholate (3.47 Ci/mmol) and [3H]-estrone-3-sulfate 
(53 Ci/mmol) were purchased from NEN Life Science Products AG (Boston, MA, 
USA) and Perkin Elmer Life Sciences (Boston, MA). [3H]-Demethylphalloin (8.9 
GBq/mmol) was synthesized as described [10]. For all transport experiments 
demethylphalloin was used as labeled substrate. It is structurally very similar to 
phalloidin and has been shown to be a biological equivalent of phalloidin and to be 
transported by the same Oatps/OATPs as phalloidin in mammalian liver [3, 11-13] . 
[3H]-Dihydromicrocystin-LR (1.1x 10 8 Bq/mol) was prepared as described [14]. All 
chemicals were obtained from commercial sources and were of the highest degree of 
purification available. 
 
Isolation of skate hepatocytes I Skate hepatocytes were prepared by collagenase 
perfusion of isolated livers as previously described [15]. Cells were then maintained 
on ice in an elasmobranch Ringer buffer (270 mM NaCl, 4 mM KCl, 2  mM CaCl2, 3 
mM MgCl2, 8 mM NaHCO3, 1 mM KH2PO4, 0.5 mM Na2SO4, and 350 mM urea) [15]. 
For transport experiments cell suspensions were prewarmed in a 15 °C water bath. 
Cells were normally used for transport experiments within 3 hours after isolation. 
 
Functional characterization in skate hepatocytes I Hepatocyte suspensions (15 
°C) were diluted in elasmobranch Ringer buffer [16] to approximately 45 mg cells 
(wet weight) per milliliter. All transport studies were conducted at 15 °C. They were 
initiated by adding cell suspension (1.9 – 2.08 ml) to incubation solution (0.02 – 0.2 
ml), resulting in a total assay volume of 2.1 ml per data point (2 zero points, 4 uptake 
points, 3 standards). The incubation solution consisted of elasmobranch Ringer 
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buffer supplemented with the radioactively labeled compounds and the inhibitor 
concentrations as given in the figure legends. Unspecific binding of isotopes was 
accounted for by subtracting zero time point values from the timed transport values. 
Standards were used to transform cell-associated radioactivity into molar amounts of 
tracer uptake. Unless stated otherwise, all transport studies were performed in 
quadruplicates in at least two separate cell preparations.   
 
Functional characterization in Xenopus laevis oocytes I For in vitro synthesis of 
cRNA, the cDNA clones of Oatp1d1 [8], Ostα/β [17]  and OATP1C1 [9] were 
linearized with XhoI and NotI, respectively. Capped cRNA was synthesized using the 
mMESSAGE mMACHINE T3 and T7 Kit (Ambion, Austin, TX, U.S.A.). Xenopus 
laevis oocytes were prepared and handled as described previously [3]. After an 
overnight incubation at 18 °C healthy oocytes were injected with 50 nl water or with 5 
ng Oatp1d1-cRNA, 2 ng Ostα/β-cRNA or 5 ng OATP1C1-cRNA. After 3 days in 
culture, transport of [3H]-demethylphalloin, [3H]-estrone-3-sulfate, [3H]-
dihydromicrocystin-LR or [125l]-L-thyroxine  was measured at 25 °C in a medium 
containing 100 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 10 mM 
HEPES/Tris, pH 7.5 as described previously [3].  
Kinetic studies with phalloidin and microcystin-LR were determined at 30 min which 
was within the initial linear uptake range (not shown). The obtained values were 
corrected for the values measured in water-injected oocytes and were fitted to the 
Michaelis-Menten equation using nonlinear regression analysis to obtain the kinetic 
parameters. 
 
Statistical analysis I Cis-inhibition of phalloidin transport into skate hepatocytes was 
analyzed using ANOVA (analysis of variances) for one-way analysis. As a post test, 
Dunnett’s test was performed if overall p<0.05, which was considered to be 
statistically significant. 
Substrate specificities of Oatp1d1, Ostα/β and OATP1C1 were compared with 
transport in water-injected control oocytes by the unpaired Student’s t test. Statistical 
significance was indicated by p<0.05. 
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3. 4 Results 
Phalloidin transport into skate hepatocytes I To determine whether phalloidin is 
taken up into skate hepatocytes, the structural phalloidin analogue demethylphalloin 
was used. As a control for transport competent skate hepatocytes, taurocholate 
uptake was determined in parallel. As illustrated in Fig. 1, isolated skate hepatocytes 
demonstrated predominant sodium-independent taurocholate uptake as previously 
shown [16]. Approximately 60 % of total taurocholate uptake at 60 min were 
observed within the first 10 min of incubation (Fig. 1A). Similar sodium-independent 
uptake was also seen for phalloidin although its uptake into skate hepatocytes was 
slower (uptake at 10 min: ~ 40% of uptake at 60 min) as compared to taurocholate 
(Fig. 1B). Furthermore, after an initial rapid uptake phase time-dependent phalloidin 
did not level of, but continued to rise steadily up to 60 min. However, initial linear 
uptake rates (1 min uptake values) showed clear saturability with increasing 
substrate concentrations (Fig. 2) with an apparent Km-value of 0.4 ± 0.1 µM and a 
Vmax-value of 10.1 ± 0.3 fmol/mg protein x min-1. These data strongly indicate 
carrier-mediated uptake of phalloidin into skate hepatocytes. 
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Fig.1 
Time course of taurocholate (A) and phalloidin (B) transport into skate hepatocytes I Skate 
hepatocytes were incubated in elasmobranch Ringer buffer with 10 µM taurocholate (A) or 1 µM 
demethylphalloin (B). The incubation buffer contained either 270 mM sodium (●) or 270 mM choline 
(○) to determine the portion of sodium-independent transport. Substrate uptake was determined at the 
time intervals indicated and presented as % of total uptake at 60 min. Values represent the means ± 
SE of duplicate measurements in three separate cell preparations. 
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Fig. 2 
Saturation kinetics of phalloidin transport into skate hepatocytes I Skate hepatocytes were 
incubated in standard elasmobranch Ringer buffer supplemented with increasing concentrations of 
phalloidin (0.15 – 6 µM). Initial linear transport was determined at 1 min. Values represent the means 
± SE of quadruplicate measurements in two separate cell preparations. Values were fitted to 
Michaelis-Menten equation using nonlinear regression analysis to obtain the kinetic parameters.  
 
Inhibition studies of phalloidin transport into skate hepatocytes I Because 
phalloidin has been shown to be taken up into rat and human livers by members of 
the OATP/SLCO superfamily of solute carriers [1, 3, 11] and because an ancient 
Oatp, Oatp1d1, has been identified in skate liver [8], additional experiments 
examined whether an organic anion transport protein or even Oatp1d1 is involved in 
phalloidin transport. For this purpose, the inhibition pattern of phalloidin transport into 
skate hepatocytes was measured using typical substrates and potential inhibitors of 
mammalian liver Oatps/OATPs [1, 2]. The latter have previously been established or 
suggested as Oatp1d1 substrates [3, 4, 6, 8 ]. As illustrated in Fig. 3, the strongest 
inhibitor of [3H]-demethylphalloin transport was unlabeled phalloidin, which is 
consistent with demethylphalloin being a structural and biological equivalent of 
phalloidin. From 40-60% inhibition of uptake was also found for the well known 
Oatp/OATP substrates estrone-3-sulfate, taurocholate and related bile salt 
derivatives, the organic dye BSP, the organic anion transport inhibitors cyclosporin A 
and probenecid. In contrast, digoxin and microcystin-LR at a concentration of 10 µM 
did not inhibit phalloidin uptake to a significant extent. 
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Fig. 3 
Cis-inhibition of phalloidin transport into skate hepatocytes I 1 µM demethylphalloin transport into 
skate hepatocytes at 1 min was determined in standard elasmobranch Ringer buffer in the absence 
(control) and presence of various inhibitors, the concentrations of which were chosen on the basis of 
previously estimated Km-values of Oatp-mediated substrate uptake [1, 3] and of the inhibition pattern 
of Oatp1d1-mediated estrone-3-sulfate uptake [8].  Inhibitor concentrations were: Phalloidin (10 µM), 
estrone-3-sulfate (E3S, 50 µM), taurocholate (50 µM), taurochenodeoxycholate (TCDCA, 50 µM), 
chenodeoxycholate (CDCA, 50 µM), bromosulfophthalein (BSP, 10 µM), probenecid (500 µM), 
cyclosporine A (CycloA,10 µM), digoxin (50 µM), microcystin-LR (10 µM). Results are given as percent 
of control uptake. Values are given as means ± SE of quadruplicate measurements in three separate 
cell preparations.   
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Because microcystin-LR has been shown to be transported by all major rat and 
human liver Oatps/OATPs including Oatp1b2, OATP1B1 and OATP1B3 [4], which all 
share an amino acid sequence identity greater than 40% with skate Oatp1d1, and 
because the absence of significant inhibition of demethylphalloin uptake at a 
concentration of 1 µM (~3 times above the Km-value) by 10 µM microcystin-LR does 
not exclude the possibility that microcystin-LR might represent a low affinity substrate 
of Oatp1d1, a more detailed analysis of the inhibition kinetics was performed.  As 
illustrated in Fig. 4, strong cis-inhibition of demethylphalloin uptake was only 
observed if the microcystin-LR concentrations were increased well above 100 µM 
(estimated Ki-value ~ 150 µM). Furthermore, the Dixon-plot analysis is consistent 
with a competitive type of inhibition. These results support the assumption that 
microcystin-LR might indeed represent a low affinity substrate for the skate liver 
phalloidin uptake system (i.e. possibly Oatp1d1). 
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Fig. 4 
Dixon plot of inhibition of phalloidin transport by microcystin-LR into skate hepatocytes I  
Phalloidin transport at 1 min into skate hepatocytes was determined in standard elasmobranch Ringer 
buffer supplemented with the indicated substrate concentrations (0.2, 0.4, 0.8 µM) in the absence or 
presence of increasing concentrations of microcystin-LR (10, 30, 60, 100, 150, 230 µM). Data 
represent the means ± SE of quadruplicate determinations in one representative out of two cell 
preparations. Estimated Ki-values in both experiments amounted to ~ 152 and 160 µM, respectively. 
 
Phalloidin and microcystin-LR transport into Oatp1d1 expressing Xenopus 
laevis oocytes I To directly investigate the hypothesis that Oatp1d1 is responsible 
for phalloidin and microcystin-LR transport into skate hepatocytes, transport studies 
in cRNA injected Xenopus laevis oocytes were performed. Thereby, the transport 
properties of Oatp1d1 were compared also to the alternative skate organic anion 
transporter Ostα/β  [17] and to the mammalian Oatp1d1 orthologue OATP1C1 [8, 9].  
The organic anion estrone-3-sulfate was included as a standard substrate to control 
for transport competent oocytes and thyroxine served as a control substrate for 
OATP1C1 [9]. As summarized in Table 1, phalloidin uptake was stimulated twofold in 
Oatp1d1 expressing oocytes as compared to water injected oocytes. In contrast, 
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Ostα/β-cRNA injected oocytes exhibited virtually no increased phalloidin uptake 
although Ostα/β was effectively expressed at the surface of the oocytes as indicated 
by the markedly increased uptake of estrone-3-sulfate. Also, no increased phalloidin 
uptake was found in OATP1C1 expressing oocytes despite an approximately 8-fold 
stimulation of the control substrate thyroxine (Table 1).  In addition to phalloidin, 
Oatp1d1-expressing oocytes also showed an approximately 3-fold stimulation of 
microcystin-LR uptake, whereas microcystin-LR was less well transported by Ostα/β 
(Table 1). These results demonstrate that phalloidin and microcystin-LR are transport 
substrates of skate liver Oatp1d1.  
 
Table 1 
Transport of phalloidin and microcystin-LR by Oatp1d1, Ostα/β and OATP1C1 in water 
and cRNA-injected Xenopus laevis oocytesa 
Substratesb Water 
(fmol/oocyte 
 x 30 min) 
Oatp1d1 
(fmol/oocyte  
x 30 min) 
Ostα/β 
(fmol/oocyte 
 x 30 min) 
OATP1C1 
(fmol/oocyte 
 x 30 min) 
Phalloidin 
(4µM) 
     60.2 ± 5.8 122.1± 16.7* 72.5 ±   6.1 60.3 ± 5.3 
Microcystin-LR 
(4µM) 
3.8 ± 0.3    9.9 ±  2.4*    6.0 ±   2.3*  
Thyroxine 
(5 nM) 
1.1 ± 0.1       8.9 ± 1.3* 
Estrone-3-Sulfate 
(50 nM) 
1.3 ± 0.2 16.9 ±   5.2* 46.2 ±  14.3*      2.1 ± 0.2* 
Estrone-3-Sulfate 
(500nM) 
5.7 ± 1.0 47.6 ± 11.6* 342.0 ±  47.9*  
 
aOocytes were injected with water, 5 ng Oatp1d1-cRNA, 2 ng Ostα/β-cRNA or 5 ng OATP1C1-cRNA. 
Substrate uptake was measured at 30 min in10-40 oocytes in two separate experiments. 
bThyroxine was included as a control substrate for OATP1C1 (10). Estrone-3-sulfate served as control 
for functionally competent transporter expression levels. * Significantly different from water-injected 
oocytes (p< 0.05). 
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Finally, saturation kinetics analysis of Oatp1d1 mediated phalloidin and microcystin-
LR transport was performed in cRNA-injected X. laevis oocytes. Because preliminary 
experiments demonstrated that initial transport rates for both cyclic oligopeptides 
increased linearly over at least 45 min (results not shown), uptake rates were 
measured at 30 min for all kinetic experiments. As indicated in Fig. 5, Oatp1d1 
mediated uptake of increasing concentrations of phalloidin up to 10 µM exhibited 
saturability with an apparent Km-value of 2.2 ± 0.8 µM (Fig. 5A) and an apparent 
Vmax of 0.5 ± 0.1 fmol/oocyte per min. Furthermore, apparent saturation kinetics was 
also found for initial uptake rates of microcystin-LR, where the apparent Km-value 
amounted to 26.9 ± 9.9 µM (Fig. 5B) and the Vmax to 0.9 ± 0.2 fmol/oocyte per min. 
Hence, the affinity of Oatp1d1 for microcystin-LR is approximately 10-fold lower than 
its affinity for phalloidin, which provides an explanation for the failure of 10 µM 
microcystin-LR to inhibit the uptake of 1 µM phalloidin in skate hepatocytes (see Fig. 
3). These results strongly support the hypothesis that Oatp1d1 is responsible for 
uptake of both phalloidin and microcystin-LR into skate hepatocytes.  
59 
CHAPTER 3 I Results 
 
 
Fig. 5 
Saturation kinetics of phalloidin (A) and microcystin-LR (B) uptakes into Xenopus laevis 
oocytes I Oocytes were injected with 5 nl water or 5 ng Oatp1d1 cRNA. After three days in culture, 
transport was determined over the initial 30-min period at increasing concentrations of phalloidin or 
microcystin-LR, respectively. Measurements were performed at 25 °C in two separate oocyte 
preparations (9-12 oocytes). Data represent the means ± SE.  Values were fitted to Michaelis-Menten 
using nonlinear regression analysis to obtain the kinetic parameters. 
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3. 5 Discussion 
The present study provides direct evidence that Oatp1d1 mediates phalloidin and 
microcystin-LR uptake into skate liver. This conclusion is derived from the following 
observations: 1) Isolated skate hepatocytes exhibited high affinity uptake of phalloidin 
with an apparent Km of ~ 0.4 µM (Fig. 2). 2) Phalloidin uptake into skate hepatocytes 
could be inhibited by typical Oatp/OATP substrates (Fig. 3) and in an apparent 
competitive manner, also by high concentrations of microcystin-LR (Fig. 4). 3) 
Oatp1d1 expressing oocytes exhibited high affinity phalloidin (apparent Km ~ 2.2 µM) 
and lower affinity microcystin-LR (apparent Km ~ 27 µM) uptake (Fig. 5). And 4) 
Ostα/β, the second so far identified organic anion transporter of skate hepatocytes, 
did not show phalloidin and only minor microcystin-LR transport, when expressed in 
X. laevis  oocytes (Table 1). Hence, Oatp1d1 mirrors the oligopeptide transport 
properties of the mammalian liver Oatps/OATPs, supporting the notion that Oatp1d1 
represents an evolutionarily ancient precursor of the mammalian liver transporters [8]. 
In mammalian liver, phalloidin uptake has been shown to be mediated by Oatp1b2 in 
the rat [3] and by OATP1B1 and to a lesser degree also by OATP1B3 in man [3, 11]. 
In contrast, no phalloidin transport has been observed with Oatp1a1, Oatp1a4, 
OATP1A2 and OATP2B1 [3]. Hence, only the liver specific transporters of the 
OATP1B subfamily [18] exhibited phalloidin transport in mammalian species, 
whereas the more widely expressed members of the OATP1A and OATP2B 
subfamilies [18] did not accept phalloidin as a transport substrate. The affinities (Km-
values) of the mammalian transporters for phalloidin have been reported to be 5.7 
µM (Oatp1b2), 7.5 µM (OATP1B3) and 17 µM (OATP1B1) [3]. This study 
demonstrates that even skate hepatocytes exhibit high affinity phalloidin uptake 
although phallotoxins do not represent typical water borne organic substances. 
However, as a cyclic oligopeptide phalloidin belongs to the Oatp/OATP substrates [3, 
11], and skate hepatocytes express the evolutionarily ancient Oatp1d1 [8], which 
mediated phalloidin uptake when expressed in Xenopus laevis oocytes (Table 1, Fig. 
5). These findings indicate that Oatp1d1 is responsible for the phalloidin uptake 
activity of skate hepatocytes, although the approximately 5-fold difference in the 
apparent Km-values between phalloidin uptake into hepatocytes (~ 0.4 µM, Fig. 2) 
and Oatp1d1 expressing oocytes (~ 2.2 µM, Fig. 5) cannot exclude the possible 
involvement of additional, so far unidentified transport systems. The only other so far 
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known multispecific organic anion transporter of skate hepatocytes, Ostα/β, did not 
exhibit any phalloidin transport activity when expressed in X.  laevis oocytes (Table 
1). Interestingly, OATP1C1, which is predominantly expressed in human brain and 
testis [9] and which shares the highest overall amino acid sequence identity with the 
skate liver Oatp1d1 [8] , did also not show any phalloidin transport activity (Table 1). 
Hence, phalloidin transport appears to be a characteristic feature of liver specific 
Oatps/OATPs in both mammalian as well as in skate livers.   
In addition to phalloidin, Oatp1d1 also transports the water borne cyclic oligopeptide 
microcystin-LR (Table 1, Fig. 5). This protein phosphatase inhibitor has been 
previously shown to be transported into skate liver by a multispecific organic 
substrate transporter that can be inhibited by a wide range of organic anions such as 
bromosulfophthalein (BSP), bile salts (e.g. cholate, taurocholate), rifampicin, 
rifamycin B, rose bengal and trypan blue [6]. These latter compounds are typical 
Oatp/OATP substrates and many of them also inhibit Oatp1d1 [8]. Hence, the 
previous studies are consistent with Oatp1d1 being responsible for microcystin 
uptake into skate liver, although the affinity of Oatp1d1 for microcystin was found to 
be approximately 10-fold lower (Km ~27 µM, Fig. 5) as compared to its affinity for 
phalloidin (Km ~2.2 µM, Fig. 5). Furthermore, in skate hepatocytes microcystin 
inhibited phalloidin uptake with a Ki-value of approximately 150 µM (Fig. 4), which 
further supports the relatively low affinity of Oatp1d1 for microcystin-LR. With respect 
to the discrepancy between the Km- and Ki-values, it has to be noted that the 
experimental validation of the transport kinetics were hampered by the considerable 
oocyte toxicity of microcystin-LR above concentrations of 25 µM [4]. Nevertheless, 
the Km-value of Oatp1d1 for microcystin (~27µM) compares well with the 
corresponding Km-values of the human transporters OATP1B1 (~7 µM), OATP1B3 
(~9 µM) and OATP1A2 (~20 µM) [4]. In addition, it is consistent with the observation 
that 100 µM taurocholate (KmOatp1d1 ~85 µM; [8]) inhibits microcystin-LR (10 µM) 
uptake into skate hepatocytes by approximately 50 % [6]. Hence, low affinity uptake 
of microcystin-LR into skate liver can explain the high sensitivity of microcystin 
induced hepatotoxicity to inhibition of hepatocellular uptake by a variety of 
Oatp/OATP substrates [6]. In fact, the broad substrate specificity of skate and 
mammalian hepatic Oatps/OATPs offers the opportunity to prevent and/or 
antagonize microcystin induced liver injury by parenteral administration of a variety of 
62 
CHAPTER 3 I Discussion 
organic anions including BSP, bile salts, cyclosporine A or rifampicin. A similar 
conclusion has been reached recently also with respect to amatoxin induced liver 
injury, as the main poison of the green death cap (Amanita phalloides), α-amanitin, is 
taken up into human liver by OATP1B3 [5]. Hence, identification and characterization 
of the uptake carriers involved can be of considerable importance for prevention 
and/or treatment of toxin induced liver injury in man as well as in various animal 
species. The latter also includes now the little skate Leucoraja erinacea, which might 
be subject to occasional intoxication with marine toxins such as the phosphatase 
inhibiting microcystins.   
In conclusion, the present study identifies Oatp1d1 as the phalloidin and microcystin-
LR uptake system in skate liver. Because the same cyclic oligopeptides are also 
transported by the liver specific Oatps/OATPs in rodents and in men, the data 
support the notion that Oatp1d1 represents an evolutionarily ancient precursor of the 
mammalian liver Oatps/OATPs. Furthermore, the present observations provide 
further evidence that Oatp/OATP-mediated toxin uptake is important for certain forms 
of toxic liver injury such as microcystin induced hepatocellular necrosis.  
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CHAPTER 4 I Abstract 
4.1 Abstract  
Many organic anion transporting polypeptides (Oatps) have overlapping substrate 
specificities and mediate uptake of a wide variety of structurally unrelated 
compounds. For certain Oatps specific substrates have been reported. Among the 
well characterized members of the OATP1A subfamily, Oatp1a4 is a high affinity 
digoxin transporter while Oatp1a1 does not transport digoxin. To identify amino acids 
that are important for Oatp1a4-mediated transport, we expressed chimeras between 
Oatp1a4 and Oatp1a1 in Xenopus laevis oocytes and used digoxin transport as a 
functional tool. Based on the results with these chimeras we performed site-directed 
mutagenesis and identified three amino acid residues (F328, S334 and M361) that 
when mutated to the residues found in Oatp1a1, resulted in reduced digoxin 
transport. Kinetic analysis revealed that these mutations reduced the apparent affinity 
of Oatp1a4 to digoxin. We then measured uptake of the general Oatp substrates 
taurocholate, estradiol-17β-glucuronide and D-penicillamine2,5-enkephalin (DPDPE) 
in oocytes as well as in HeLa cells expressing the mutant proteins. Consistent with 
our hypothesis that the mutated amino acid residues are important for overall 
Oatp1a4-mediated uptake, transport of all tested substrates was reduced in both 
expression systems. Furthermore, similar as for digoxin, the affinity for DPDPE was 
also reduced. In summary, we have identified three amino acid residues, F328, S334 
and M361, which are essential for transport mediated by Oatp1a4. However, we do 
not yet know whether these amino acid residues are directly involved in substrate 
binding or whether they affect the three-dimensional structure of the transporter.  
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4.2 Introduction 
Organic anion transporting polypeptides (animals: Oatps; human: OATPs) form a 
superfamily of 12 transmembrane helices (TMH) proteins that can currently be 
subdivided into 6 mammalian families (≥ 40 % amino acid sequence identities, 
OATP1-6) and 13 subfamilies (≥ 60 % amino acid sequence identities) [1]. The 
OATP1 family comprises the rodent Oatp1a1 (gene symbol Slco1a1), Oatp1a3 
(Slco1a3), Oatp1a4 (Slco1a4), Oatp1a5, (Slco1a5), Oatp1a6 (Slco1a6), Oatp1b2 
(Slco1b2), as well as the human OATP1A2 (SLCO1A2), OATP1B1 (SLCO1B1), 
OATP1B3 (SLCO1B3) and OATP1C1 (SLCO1C1). Most of these are multispecific 
carriers that accept a variety of amphipathic organic compounds including bile salts, 
organic anionic dyes, steroid conjugates, thyroid hormones, prostaglandins, anionic 
oligopeptides, numerous drugs and other xenobiotics [2]. Members of other families, 
such as the prostaglandin transporters (PGTs) of the OATP2 family which transport 
only eicosanoids or OATP2B1 which mainly transports the steroid-conjugates 
estrone-3-sulfate and dehydroepiandrosterone sulfate, have a much narrower 
substrate specificity [3, 4]. Characterization of single Oatps/OATPs so far has 
concentrated on functional aspects of the multispecificity, i.e. on apparent affinity 
constants and on cis-inhibition patterns of the different substrates [2, 3, 5]. Such 
inhibition experiments performed with Oatp1a4 suggested that there might be 
different substrate recognition sites for digoxin and estradiol-17β-glucuronide [6]. 
Only a few studies have been reported investigating the molecular basis of the 
substrate specificity for members of the OATP-gene superfamily and identified 
structural elements involved in substrate binding and/or transport. Experiments with 
the PGTs from human, rat and mouse and some of their chimeras suggested that the 
C-terminal half of the protein is important for the apparent affinity of prostaglandin E2 
[7]. Using cysteine-scanning mutagenesis the same group mapped the substrate-
binding site of the rat PGT to TMH 10 [8] and identified conserved cationic amino 
acids important for prostaglandin transport [9]. However, no such studies have been 
performed for the multispecific Oatps such as rat Oatp1a1, Oatp1a4 and Oatp1a5. 
Besides common substrates such as the bile salt taurocholate, the steroid–conjugate 
estradiol-17β-glucuronide, and the opioid peptide D-penicillamine2,5 enkephalin 
(DPDPE) [10, 11] there are specific compounds that can be used to distinguish 
between Oatp1a1, Oatp1a4 and Oatp1a5 on a functional level. Bromosulfophthalein 
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is a good substrate for Oatp1a1 and Oatp1a5 but is not transported by Oatp1a4. On 
the other hand, digoxin is a high affinity substrate for Oatp1a4 (Km ~ 0.24 µM) and is 
also transported by Oatp1a5 but is not a substrate for Oatp1a1 [11]. 
Based on these substrate differences and the overall high amino acid sequence 
identity of 77%, we hypothesized that digoxin transport in combination with chimeras 
between Oatp1a1 and Oatp1a4 and site-directed mutagenesis should allow us to 
identify distinct regions and/or individual amino acids that are important for Oatp1a4-
mediated substrate recognition and transport. 
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4.3 Materials and Methods 
Animals I Female Xenopus laevis were purchased from the African Xenopus facility 
c.c., Noordoek, South Africa. The frogs were maintained and treated according to 
NIH guidelines. 
 
Materials I All oligonucleotides were ordered from Microsynth (Balgach, 
Switzerland). Cell culture media and reagents were obtained from Invitrogen 
(Groningen, The Netherlands). Radiolabeled [3H]-digoxin (9.0 Ci/mmol), [estradiol-
6,2-3H]-estradiol-17β-D-glucuronide (45.0 Ci/mmol) and [tyrosyl-2,6-3H(N)]-D-
penicillamine2,5 enkephalin (DPDPE; 40.0 Ci/mmol) were purchased from 
PerkinElmer Life Sciences (Boston, MA). [3H]-Taurocholic acid was obtained from 
American Radiolabeled Chemicals Inc. (St. Louis, MO). Unlabeled DPDPE was 
obtained from BACHEM (Bubendorf, Switzerland).  
Unless stated otherwise, all other chemicals were provided in the highest degree of 
purification available from Sigma (St. Louis, MO) or Fluka (Buchs, Switzerland). 
 
Construction of chimeras and mutants I In order to avoid problems with different 
RNA stabilities due to different 3’ untranslated regions, all the constructs were cloned 
into the so-called Oatp1a1 backbone. This Oatp1a1 backbone was constructed as 
follows: The Oatp1a1 cDNA (GenBank accession number NM_017111) in the 
pSPORT1 vector [12] was cut with the restriction enzymes NcoI and BsmI. The 
resulting overhangs were filled in with Klenow enzyme (Amersham Biosciences, 
Buckinghamshire HP7 9NA, England) and after dephosphorylation with calf intestinal 
alkaline phosphatase (Promega, Madison, WI, U.S.A.), the Oatp1a1 backbone was 
gel purified. This vector allowed cloning of blunt ended cDNAs between bases 89 
and 2142 of the original Oatp1a1 construct resulting in identical 3’ and 5’ 
untranslated sequences. To be able to detect all constructs with the same antibody, a 
6-His tag was attached to the Oatp1a1 and Oatp1a4 open reading frame (ORF) by 
PCR amplification with the primers Oatp1a1f90 and Oatp1a1rHis for Oatp1a1 and 
Oatp1a4f122 and Oatp1a4rHis for Oatp1a4 (Table 1). To reduce PCR related 
mutations, all amplifications were performed with the proofreading enzyme Pfu Turbo 
DNA polymerase (Stratagene, La Jolla, CA, U.S.A.). After amplification of the His-
tagged Oatp1a1 and Oatp1a4 ORFs, they were cloned into the Oatp1a1 backbone. 
The correct orientation and sequence were confirmed by sequencing of both strands 
69 
CHAPTER 4 I Material and Methods 
on an ABI PRISM® 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, 
U.S.A.). In functional assays with X. laevis oocytes, the His-tagged constructs could 
not be distinguished from the normal proteins.   
For the construction of the chimeras, an overlap PCR approach was used. In a first 
round of PCR, two overlapping fragments (chimf and chimr primers are at the same 
position on the two cDNA strands and thus overlap) were produced with templates 
and primers according to Tables 1 and 2. After gel-purification of the amplification 
products, they were used as templates for a second round of PCR using the flanking 
primers (reverse and universal, Tables 1 and 2). These final amplicons contained the 
multiple cloning site of the original pSPORT1 vector and therefore were cut with the 
restriction enzymes SalI and NotI. After gel-purification of the digested fragments 
they were directionally cloned into a SalI-NotI cut pSPORT1 vector and their correct 
sequence was verified by sequencing both strands. 
To introduce single amino acid mutations a similar overlap PCR approach was used. 
The middle primers (Table 2) contained the desired mutation and together with the 
flanking “reverse” and “universal” primers the mutation was introduced after two 
rounds of PCR. All constructs were verified by sequencing both strands. 
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Table 1   
Primers used to prepare the different chimeras and mutants 
Primer Sequence (5’ to 3’)  
 Primers to introduce the His tag  
Oatp1a1f90 GAAGAAACAGAGAAAAAGATTGCA  
Oatp1a1rHis TTAATGGTGATGGTGATGATGCAGCTTCGTTTTCAGTTCTCC  
Oatp1a4f122 GGAAAATCTGAGAAAAGGGTTGCA  
Oatp1a4rHis TCAATGGTGATGGTGATGATGGTCCTCCGTCACTTTCGACCT  
 Primers for chimeras Chimera 
Reverse CAGGAAACAGCTATGAC All 
Universal TGTAAAACGACGGCCAGT All 
Chim1f ATTTACATGCTTTTCATCCTTA 1/2 
Chim1r TAAGGATGAAAAGCATGTAAAT 1/2 
Chim1af TTACTGTCAAGAAAGCTGCA 3 
Chim1ar TGCAGCTTTCTTGACAGTAA 3 
 Primers for mutations Mutation1
Mut1for AGTGTTCTCCAGGTGAATGCATTTATC F328V 
Mut1rev GATAAATGCATTCACCTGGAGAACACT F328V 
Mut2for CTCCAGTTCAATGGCTTTATCAATTCA A330G 
Mut2rev TGAATTGATAAAGCCATTGAACTGGAG A330G 
Mut3for GCATTTATCAATAAATTTACCTTCATG S334K 
Mut3rev CATGAAGGTAAATTTATTGATAAATGC S334K 
Mut4for TCCACTGCTGAGGCAGTCTTCCTTATG V353A 
Mut4rev CATAAGGAAGACTGCCTCAGCAGTGGA V353A 
Mut5for ACTGCTGAGGTAATATTCCTTATGGGT V354I 
Mut5rev ACCCATAAGGAATATTACCTCAGCAGT V354I 
Mut6for ATGGGTCTTTATAGCTTACCTCCAATA M361S 
Mut6rev TATTGGAGGTAAGCTATAAAGACCCAT M361S 
 
  1 F328V means that the Phe-328 was replaced by a valine and so on. 
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Table 2  
Templates and primers used to construct the different chimeras 
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1 Oatp1a1 
Oatp1a4 
Reverse 
Chim1f 
Chim1r  
Universal 
Amplification 
product of        
1st PCR 
Reverse Universal 
2 Oatp1a4 
Oatp1a1 
Reverse 
Chim1f 
Chim1r  
Universal 
Amplification 
product of        
1st PCR 
Reverse Universal 
3 Oatp1a1 
Oatp1a4 
Reverse 
Chim1af 
Chim1ar 
Universal 
Amplification 
product of           
1st PCR 
Reverse Universal 
 
1 The Oatp1a1 and Oatp1a4 templates were the His-tagged constructs described in the   Materials and 
Methods section. 
 
 
Functional characterization in Xenopus laevis oocytes I For in vitro synthesis of 
cRNA, the cDNA clones were linearized with NotI and capped cRNA was 
synthesized using the mMESSAGE mMACHINE T7 kit (Ambion, Austin, TX, U.S.A.). 
Oocytes were prepared and handled as described previously [13] and after an 
overnight incubation at 18 °C, healthy oocytes were injected with 50 nl water or 5 ng 
of the respective cRNA. After 3 days in culture, transport of radiolabeled substrates 
was measured at 25 °C in a medium containing 100 mM choline chloride, 2 mM KCl, 
1 mM CaCl2, 1 mM MgCl2 and 10 mM HEPES/Tris, pH 7.5, as described previously 
[14]. Kinetics were determined at 15 minutes which was within the initial linear range 
(not shown). The obtained values, corrected with the values measured with water-
injected oocytes, were fitted to the Michaelis-Menten equation using nonlinear 
regression analysis to obtain kinetic parameters. 
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Immunodetection of His-tagged proteins I Oocytes were injected with either 50 nl 
of water or with 5 ng of the respective cRNAs. After three days in culture they were 
fixed with 3 % paraformaldehyde in phosphate buffered saline (PBS) and after two 
washes with PBS frozen in Tissue Freezing Medium (Electron Microscopy Sciences, 
Fort Washington, PA, U.S.A.). Sections (10 µm) immobilized on gelatine coated 
slides were washed three times for 30 seconds with PBS, incubated for 5 minutes 
with 0.25 % Triton X-100 in PBS, and then washed three times for 30 seconds with 
PBS. Afterwards, the sections were blocked for one hour in 5 % normal goat serum 
and 0.1 % Triton X-100 in PBS. Following a wash step (3 times 10 minutes PBS), the 
sections were incubated for one hour with the Penta-His Antibody (QIAGEN GmbH, 
Hilden, Germany) at a 1:25 dilution in 2 % normal goat serum, 0.1 % Triton X-100 in 
PBS. After a wash step (three times 10 minutes PBS), the sections were incubated 
with a monoclonal Cy3 labeled goat-anti-mouse antibody (Jackson ImmunoResearch 
Laboratories, West Grove, PA, U.S.A.) at a 1:300 dilution in 2 % normal goat serum, 
0.1 % Triton X-100 in PBS. After a final wash step (four times 10 minutes PBS) the 
sections were mounted and pictures were taken with a Zeiss Axiovert 25 (Karl Zeiss 
AG, Feldbach, Switzerland). 
 
Cell culture and preparation of vaccinia virus I All cells were grown in monolayer 
cultures in a humidified incubator at 37 °C, in an atmosphere of 5 % CO2. For the 
vaccinia viral stock preparation, BHK-21 cells (European Collection of Cell Culture, 
Wiltshire, UK) were used while transport studies were undertaken with HeLa cells 
(European Collection of Cell Culture, Wiltshire, UK). BHK-21 cells were maintained in 
Eagle’s Minimal Essential medium supplemented with 2 mM L-glutamine, 1 mM 
sodium pyruvate, 0.1 mM non essential amino acids, 10% fetal bovine serum and 1% 
penicillin/streptomycin. High titer stocks of the modified vaccinia virus Ankara 
expressing the bacteriophage T7 RNA polymerase (MVA-T7pol, kindly provided by 
G. Sutter, Paul-Ehrlich-Institute, Langen, Germany) were obtained by infecting BHK-
21 cells grown to subconfluence in 75 cm2 culture flasks with virus (reconstituted 
from the stock obtained from G. Sutter) in 3 ml of medium for 1 hour at 37 °C [15]. 
The virus was then removed and replaced by fresh medium. Infected cells were 
incubated for 2 days at 37 °C. Cells were harvested in 5 ml fresh medium and 
underwent three rounds of freeze-thaw, first in dry ice/ethanol, then in a 37 °C bath. 
Before storage at -70 °C the virus solution was sonicated for 1 minute. To increase 
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the virus titer, BHK-21 cells were grown in 175 cm2 flasks and infected with 2 ml of 
the 1st passage virus for 1 hour, for subsequent virus passages only 1 ml was used.  
After this, 30 ml of medium were added and the cells were cultured for 2 days before 
they were harvested in 15 ml medium and processed as described above. For the 
final amplification the harvested cells were centrifuged for 10 minutes at 1000 x g 
(IEC Centra-8R, International Equipment company, NEEDHAM HTS, MA) and the 
resulting pellet was resuspended in 1 ml 10 mM Tris (pH 9) per 175 cm2 flask of 
infected cells and then underwent three rounds of freeze-thaw before 1 min of 
sonification. Before using these viral preparations in transport studies with HeLa 
cells, they were titrated by X-Gal staining as described [16] on 6-well plates.  
 
Functional characterization using recombinant vaccinia virus-infected HeLa 
cells I HeLa cells were maintained in Eagle’s Minimal Essential medium 
supplemented with 2 mM L-glutamine, 0.1 mM non essential amino acids, 10 % fetal 
bovine serum and 1% penicillin/streptomycin. Exponentially growing HeLa cells were 
harvested by trypsinisation and re-plated at a density of 1 x 105 in 1 ml growth 
medium in 24-well-plates twenty-four hours before virus adsorption and transfection.  
Adsorption and infection with the MVA-T7pol virus for transient expression was done 
as follows. The vaccinia virus was thawed on ice and after 1 min of sonification, cells 
were infected with 10 pfu/cell in serum-free OptiMEM I medium. The vaccinia virus 
was allowed to adsorb for 60 minutes at 37 °C. Preliminary studies where HeLa cells 
were infected with increasing pfu/cell (not shown) demonstrated that 10 pfu/cell 
resulted in maximal transport rates. The virus-containing medium was removed after 
60 minutes and, after washing the cells once, replaced by growth medium and 
transfection mixture. The transfection mixture consisted of 0.4 µg of expressing 
plasmid (the same cDNA used to prepare cRNA) or empty pSPORT1 as a control 
and 1 µl of the cationic lipid agent Lipofectamine™ 2000 (Invitrogen, Groningen, The 
Netherlands).  The transfected cells were then incubated for 17 to 19 hours at 37 °C.  
After washing the cells three times with prewarmed (37 °C) uptake buffer (100  mM 
NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2 and 10  mM HEPES/Tris, pH 7.4) 
transport was initiated by adding 200 µl uptake buffer containing 0.4 – 0.7 µCi 
radiolabeled substrate with sufficient unlabeled compound to achieve the indicated 
concentration. Transport was terminated at designated times by four washes with 
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ice-cold uptake buffer. Cells were lysed with 250 µl 1 % Triton X-100. Cell associated 
radioactivity was measured by scintillation counting (PerkinElmer Life Sciences, 
Boston, MA) and the protein concentration was determined using the bicinchoninic 
acid protein assay kit (Pierce, Rockford,IL) [17].  Transport in transiently transfected 
HeLa cells with radiolabeled digoxin (0.25 µM), estradiol-17β-glucuronide (1 µM), 
DPDPE (0.1 µM) and taurocholate (20 µM) was measured in triplicates over the initial 
2-minute-period. Kinetics for digoxin and DPDPE were determined at 30 seconds 
and 2 minutes respectively, which was within the linear range (not shown). Passive 
diffusion was determined by carrying out parallel experiments using the empty 
pSPORT1 vector, and this value was subtracted from the total transport determined 
in the presence of transporter DNA. Michaelis-Menten-type nonlinear curve fitting 
was carried out to obtain estimates of the maximal uptake rate (Vmax) and the 
apparent affinity constant (Km) (Sigmaplot for Windows 5.0, SPSS Inc., Chicago, IL 
and SYSTAT for Windows 8.0). All experiments were performed at least three times.  
 
Statistical analysis I Data are presented as means ± S.E. Wildtype Oatp1a4 and 
the three mutants were analyzed using ANOVA (analysis of variance) for one-way 
analysis. As a post test, Bonferroni’s Multiple Comparison Test was performed if 
overall p<0.05, which is taken as the limit denoting significant differences. 
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4.4 Results 
Digoxin transport with chimeras between Oatp1a1 and Oatp1a4 I To examine the 
structural requirements for Oatp1a4-mediated transport, we produced chimeras 
between Oatp1a1, which does not transport digoxin, and Oatp1a4, which represents 
a high affinity digoxin transporter. Chimeras (Fig. 1) were prepared based on the high 
nucleotide sequence identity with primers that were identical for Oatp1a1 and 
Oatp1a4 (Tables 1 and 2) using an overlap PCR approach. Chimera 1 and 2 were 
constructed as mirror images containing TMH 1-7 of Oatp1a1 followed by the C-
terminal TMH 8-12 of Oatp1a4 and TMH 1-7 of Oatp1a4 followed by the rest of 
Oatp1a1, respectively. Together with His-tagged wildtype Oatp1a1 and Oatp1a4 they 
were expressed in X. laevis oocytes. Initial uptake rates for digoxin were determined 
and expressed in percent of the uptake obtained for wildtype Oatp1a4-injected 
oocytes. Preliminary experiments revealed that the His-tagged Oatps transported 
typical substrates at the same rates as the wildtype Oatps (data not shown). 
Compared to Oatp1a4, only chimera 1 was able to mediate significant transport of 
digoxin (Fig. 1).  Since this construct contained the C-terminal TMH 8-12 of Oatp1a4 
and the reverse chimera 2 did not mediate digoxin transport, we concluded that TMH 
8-12 are essential for Oatp1a4-mediated transport. 
To further investigate how much of this C-terminal part of Oatp1a4 is needed for 
digoxin transport, an additional chimera was produced (chimera 3) and functionally 
tested in oocytes. In comparison to chimera 1, one additional TMH and some 
connecting amino acids, a total of 64 amino acids from Oatp1a1, were sufficient to 
completely abolish digoxin transport mediated by this chimeric protein in X. laevis 
oocytes (Fig. 1). Therefore, we concluded that this stretch of 64 amino acids from 
position 324 to 387 of Oatp1a4, is required for substrate transport and we further 
analyzed it in comparison to Oatp1a1 and Oatp1a5. 
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Fig. 1 
Digoxin transport by wildtype and chimeric Oatp1a1 and Oatp1a4 constructs into Xenopus 
laevis oocytes I Oocytes were injected with 50 nl water or 5 ng cRNA of the respective His-tagged 
constructs and after three days in culture transport of 0.5 µM [3H]-digoxin was determined at 25 °C 
with 9-12 oocytes per condition. Black boxes and thick lines represent Oatp1a1, white boxes and thin 
lines Oatp1a4. Values are given as percent of the initial transport rates obtained for wildtype Oatp1a4-
injected oocytes and correspond to the mean of three (one for chimera 3) independent experiments. 
 
 
Comparison of amino acids 324 to 387 of Oatp1a4 with Oatp1a1 and Oatp1a5 I 
In order to identify single amino acids that are important for Oatp1a4-mediated 
substrate binding and/or transport, the 64 amino acids of Oatp1a4 were compared to 
the corresponding amino acids of Oatp1a1 and Oatp1a5 (Fig. 2A). The multiple 
alignment of both Oatp1a4 and Oatp1a5 with Oatp1a1 revealed that there are only 6 
amino acid positions that differ in the digoxin transporters, Oatp1a4 and Oatp1a5, 
compared with Oatp1a1, the non-digoxin transporter (Fig. 2A, boxed). F328 of 
Oatp1a4 corresponds to a valine in Oatp1a1, A330 to a glycine, S334 to a positively 
charged lysine, V353 to an alanine, V354 to an isoleucine and M361 to a serine. As 
shown in Fig. 2B, these six amino acid residues are all located close to the 
extracellular border of TMH 7 and 8 in the predicted membrane topology of Oatp1a4.  
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Fig. 2  
Partial amino acid sequence alignment of rat Oatp1a4, Oatp1a5 and Oatp1a1 around TMH 7 and 
8 (A) and location in the predicted membrane topology of Oatp1a4 based on hydrophobicity 
analysis (B) I (A), The 64 amino acids that were replaced from chimera 1 to chimera 3 (Fig. 1) are 
shown and the amino acid residues that differ between Oatp1a1 and both Oatp1a4 and Oatp1a5 are 
boxed and labeled. (B), Location of the six amino acid residues in the predicted membrane topology of 
Oatp1a4. 
 
 
Site-directed mutagenesis of Oatp1a4 and functional characterization of 
Oatp1a4 mutants in Xenopus laevis oocytes I Because any of the identified amino 
acid residues could be important for Oatp1a4-mediated substrate transport, each of 
the six residues was changed individually in His-tagged Oatp1a4 to its counterpart 
amino acid residue in Oatp1a1 (Fig. 2, Table 1). The resulting mutant Oatp1a4 
proteins were expressed in oocytes and digoxin transport was reapplied as a 
functional tool in order to compare initial rates of digoxin transport of the mutants to 
wildtype Oatp1a4.  
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As shown in Fig. 3, digoxin transport rates of mutants A330G, V353A and V354I 
were comparable to wildtype Oatp1a4. On the other hand, digoxin transport rates 
obtained with mutants F328V, S334K and M361S were clearly reduced when 
compared to wildtype Oatp1a4.  
 
 
 
Fig. 3 
Digoxin transport by wildtype and mutated Oatp1a4 into Xenopus laevis oocytes I Oocytes were 
injected with 50 nl water or 5 ng cRNA of the respective constructs and after three days in culture 
transport of 0.5 µM [3H]-digoxin was determined at 25 °C with 9-12 oocytes per condition. Values 
represent the means ± SE of three independent experiments and are given as percent of the initial 
transport rates obtained for wildtype Oatp1a4-injected oocytes. * p < 0.05 compared to Oatp1a4. 
79 
CHAPTER 4 I Results 
Expression in Xenopus laevis oocytes and kinetic analysis of Oatp1a4 mutants 
F328V, S334K and M361S I Reduced digoxin uptake could be due to altered protein 
expression or translocation to the plasma membrane, a lowered binding affinity for 
digoxin (apparent Km) or a reduced maximal transport rate (Vmax). Therefore, we 
first tested the expression of the different mutants at the oocyte plasma membranes. 
Immunostaining of oocytes expressing the respective His-tagged constructs with an 
anti-His antibody is displayed in Fig. 4. In water-injected oocytes no fluorescence 
signal was obtained (Fig. 4A, B) while in oocytes expressing Oatp1a4 (Fig. 4C), or 
any one of the mutants F328V (Fig. 4D), S334K (Fig. 4E) and M361S (Fig. 4F) a 
clear fluorescence signal was observed in the plasma membrane indicating that the 
mutants were expressed at the membrane with no dramatic changes in protein 
expression and translocation. 
To confirm these results, we performed kinetic analysis and determined the apparent 
Km values for digoxin uptake mediated by wildtype Oatp1a4 and the three mutants. 
The results are summarized in Table 3 and revealed that the apparent Km values for 
the mutant proteins were between 6 and 45 fold higher as compared to wildtype 
Oatp1a4, which means that the affinities for digoxin were 6- to 45- fold lower for the 
mutants. The order of affinity from high to low (Oatp1a4 > F328V > M361S > S334K) 
is the same as the transport rates shown in Fig. 3 and thus suggests that 
determination of a single uptake point in the linear portion of the uptake rate in 
oocytes is a valid means to test for potential mutations before doing time consuming 
kinetics.  
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Fig. 4 
Expression of wildtype and mutated Oatp1a4 in Xenopus laevis oocytes I Oocytes were injected 
with 50 nl water or 5 ng cRNA of His-tagged wildtype or mutated Oatp1a4. After three days in culture 
oocytes were fixed and cut as described in the Materials and Methods section. Immunodetection with 
a monoclonal anti-His antibody revealed a sign at the plasma membrane whereas fluorescence was 
absent in oocytes injected with water. (A) water-injected light microscopy control; (B) water-injected; 
(C) Oatp1a4; (D) F328V; (E) S334K; and (F) M361S. 
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Table 3 
Apparent Km values for digoxin uptake mediated by wildtype Oatp1a4 and the three 
mutants  
Construct apparent Km 
(µM) 
Oatp1a4 0.3 ± 0.3 
F328V 1.7 ± 0.2 
S334K 13.4 ± 1.6 
M361S 8.8 ± 1.6 
 
Initial (15 minutes) digoxin transport rates at increasing concentrations were determined at 25 °C in 
cRNA injected X. laevis oocytes after three days in culture. Transport values of two independent 
experiments were corrected with values obtained from water-injected control oocytes and the resulting 
net carrier-mediated uptake values were fitted by nonlinear regression analysis to the Michaelis-
Menten equation. 
 
 
Taurocholate and estradiol-17β-glucuronide transport by wildtype and mutated 
Oatp1a4 in Xenopus laevis oocytes I In order to test whether the observed 
functional effects are indeed a general phenomenon for Oatp1a4-mediated substrate 
uptake, initial transport rates were measured for two well known Oatp substrates, 
taurocholate and estradiol-17β-glucuronide.  
Similarly to digoxin, we found that all three mutant proteins transported the two 
common substrates with strongly reduced transport rates when compared to wildtype 
Oatp1a4 (Fig. 5A and 5B) suggesting that the identified amino acid residues are 
important for overall Oatp1a4-mediated substrate transport.  
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Fig. 5 
Taurocholate (A) and estradiol-17β-glucuronide (B) transport by wildtype and mutated Oatp1a4 
into Xenopus laevis oocytes I Oocytes were injected with 50 nl water or 5 ng cRNA of wildtype or 
mutated Oatp1a4. After three days in culture transport of [2-3H]-taurocholic acid (20 µM) and 
[estradiol-6,2-3H]-estradiol-17β-glucuronide (0.5 µM) were determined at 25 °C with 9-12 oocytes per 
condition. Values represent the means ± SE and are given as percent of the initial transport rates 
obtained for wildtype Oatp1a4-injected oocytes. *p<0.05 compared to Oatp1a4. 
 
 
Substrate specificities of wildtype and mutated Oatp1a4 in HeLa cells I To 
validate the results obtained with the X. laevis oocytes system in a mammalian 
expression system, we used the vaccinia virus system to transiently express 
Oatp1a4 and the mutant proteins in HeLa cells. We first determined the kinetic 
parameters for Oatp1a4-mediated digoxin transport to compare them to the results 
obtained in oocytes. Digoxin transport in Oatp1a4-expressing HeLa cells was 
saturable with an apparent Km value of 0.6 ± 0.2 µM and a Vmax value of 2.9 ± 0.5 
pmol/mg protein x min-1 (data not shown). This apparent Km value for Oatp1a4-
mediated digoxin transport is very similar to the one obtained in oocytes (Table 3), 
which displayed that the two systems should yield similar results. Therefore, we 
determined initial transport rates for the Oatp1a4-specific substrate digoxin and 
estradiol-17β-glucuronide, taurocholate as well as DPDPE, substrates common to 
several Oatps, in HeLa cells transiently expressing either Oatp1a4 or one of the three 
mutant transporters. Transient expression of Oatp1a4 in HeLa cells resulted in only 
about twofold increase of digoxin, estradiol-17β-glucuronide and taurocholate 
transport rates. However, the induction of DPDPE transport was 3- to 5-fold higher in 
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HeLa cells transfected with Oatp1a4 as compared to cells transfected with the 
parental plasmid (not shown). The results in pmol/mg protein are summarized in 
Table 4 and show clearly that transport rates of the mutants are consistently lower 
than of wildtype Oatp1a4 for all the tested substrates, confirming the previous results 
obtained with oocytes expressing the transport proteins.  
 
 
Table 4 
Substrate specificity of Oatp1a4 and three mutants in HeLa cells 
 Digoxin 
 
(0.25 µM) 
Estradiol-17β- 
Glucuronide 
(1 µM) 
 
DPDPE 
 
(0.1 µM) 
Taurocholate 
 
(5 µM) 
Oatp1a4 3.2 ± 0.4 2.3 ± 0.7 1.2 ± 0.3 7.6 ± 0.7 
F328V 1.3 ± 0.7 1.3 ± 0.6 0.4 ± 0.1* 4.7 ± 1.4 
S334K 2.0 ± 0.8 1.1 ± 0.2 0.4 ± 0.1* 5.3 ± 0.5 
M361S 0.3 ± 0.3*    0 ± 0.4*     0.1 ± 0* 0.4 ± 0.2* 
 
Oatp1a4, F328V, S334K and M361S were transiently expressed in HeLa cells and transport of [3H]-
digoxin, [estradiol-6,2-3H]-estradiol-17β-glucuronide (0.5 µM), [Tyrosyl-2,6-3H(N)]-D-Penicillamine-2,5 
enkephalin (0.1 µM) and [2-3H]-taurocholic acid (20 µM) was measured over an initial 2-min period. 
The values obtained in parallel experiments using the parental plasmid were subtracted from the total 
transport rates. Means ± SE of three independent experiments are given in pmol/mg protein.  
* p<0.05 vs. wildtype Oatp1a4 
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Kinetic analysis of wildtype Oatp1a4 and the mutants F328V and S334K in HeLa 
cells I Because DPDPE transport rates for the mutants F328V and S334K were high 
enough, we performed kinetic analysis. As shown in Fig. 6 transport of increasing 
concentrations of DPDPE was measured and kinetic constants were calculated for 
wildtype Oatp1a4 (Fig. 6A), F328V (Fig. 6B) and S334K (Fig. 6C). The apparent Km 
value of 32 ± 17 µM for Oatp1a4 is in the same range as published earlier with 
oocytes by Gao et al. [18] and the Vmax value was 252.1 ± 48.6 pmol/mg protein x 
min-1 in our transient expression system. Consistent with the results for digoxin 
transport in oocytes, the apparent Km values for DPDPE transport mediated by the 
mutant proteins were approximately 5-fold higher than for wildtype Oatp1a4. 
Similarly, the maximal transport rates (Vmax values) were the same in test of 
significance for all tested constructs confirming the qualitative results obtained in 
oocytes. 
85 
CHAPTER 4 I Results 
 
Fig. 6 
Kinetics of DPDPE transport by wildtype and mutated Oatp1a4 in HeLa cells I  Oatp1a4 (A), 
F328V (B) and S334K (C) were transiently expressed in HeLa cells and transport at increasing 
concentrations of DPDPE was determined over the initial 2-min period. Data are shown as the means 
± SE of three or more independent experiments. Values were fitted to Michaelis-Menten equation 
using nonlinear regression analysis in order to obtain the kinetic parameters. 
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4.5  Discussion  
In order to determine amino acids which are essential for Oatp1a4-mediated 
substrate recognition and transport, we constructed chimeras between Oatp1a4 and 
Oatp1a1 and used site-directed mutagenesis to replace individual amino acids in 
Oatp1a4 to the corresponding amino acids of Oatp1a1. We hypothesized, that using 
digoxin transport as a functional tool to distinguish between Oatp1a1 and Oatp1a4 
function, we should be able to identify amino acid residues at or close to the Oatp1a4 
substrate binding and/or transport site. The presented results obtained with chimeric 
constructs and mutated Oatp1a4 allowed us to identify three individual Oatp1a4 
amino acids, F328, S334 and M361 that, when mutated to the corresponding amino 
acids found in Oatp1a1, resulted in a drastically compromised digoxin transport. 
Furthermore, using substrates that are transported by both, Oatp1a4 and Oatp1a1, 
we could demonstrate that these three amino acids also affect transport of common 
Oatp substrates such as DPDPE, taurocholate and estradiol-17β-glucuronide and 
therefore we conclude that they are important for overall Oatp1a4-mediated 
transport. 
As a first step towards the elucidation of the substrate binding and transport site in 
Oatp1a4, we used the high amino acid sequence identity between Oatp1a1 and 
Oatp1a4 to prepare strategic chimeras and characterized them with respect to 
digoxin transport. The initial transport rates with these chimeric proteins revealed that 
the region around TMH 7 and TMH 8 is essential for Oatp1a4-mediated transport, 
since replacing it with the sequence from Oatp1a1 abolished transport completely. 
Thus, construction of chimeras between proteins of similar amino acid sequences 
can help to narrow down important protein parts to a few amino acids as has 
previously been shown for other transport proteins such as e.g. the Na+/dicarboxylate 
and Na+/sulfate cotransporters and the peptide transporters Pept1 and Pept2 [19, 
20]. Upon closer inspection and comparison of the Oatp1a4 amino acid sequence 
with the sequences of both Oatp1a1 and Oatp1a5 in the region around TMH 7 and 8, 
six amino acid residues were identified, that could be crucial for Oatp1a4-mediated 
transport. However, only three amino acid residues were important for high affinity 
digoxin transport since the initial transport rate was clearly decreased only for the 
Oatp1a4 mutants F328V, S334K and M361S.  
Mutations and polymorphisms often result in impaired membrane localization of 
transport proteins which could explain reduced transport rates [21, 22]. However, our 
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immunofluorescence data and mainly the kinetic results obtained with transfected 
HeLa cells indicated that this is not the case for the mutations we investigated and 
displayed that the kinetics of uptake were altered. Indeed, the apparent Km values 
for the three variants of Oatp1a4 were several fold higher than the ones of wildtype 
Oatp1a4, suggesting that the identified amino acid residues are directly involved in 
substrate binding or are important to keep the protein in an optimal structure for high 
affinity substrate binding. In a previous study, we identified and characterized the 
mouse orthologue of rat Oatp1a4 [23] and found an amino acid replacement in 
mouse Oatp1a4 which corresponds to the F328V mutation characterized in this 
study. Interestingly, the mouse Oatp1a4 mediates digoxin uptake with a much lower 
affinity (Km ~ 5.7 µM) as compared to rat Oatp1a4 [23] which supports our current 
findings that F328 plays an important role in high affinity substrate binding and/or 
transport. 
Polymorphisms that do not affect protein expression have also been described and 
characterized in human OATP1B1 another multispecific member of the OATP1 family 
of transporters [24]. One of the identified polymorphisms led to an amino acid change 
of isoleucine at position 353 to threonine near TMH 7 and 8. The resulting mutant 
OATP1B1 had a 5-fold lower affinity for estrone-3-sulfate transport as compared to 
wildtype OATP1B1, suggesting that for the OATP1 family members the region 
around TMH 7 and 8 is important for substrate binding and/or transport unlike TMH 
10 which has been reported to be important for substrate recognition in the OATP2A 
subfamily [8]. 
In order to extend the studies beyond digoxin transport and test whether the 
identified amino acid residues indeed affect overall Oatp1a4-mediated substrate 
transport, we tested uptake of additional typical Oatp substrates estradiol-17-β-
glucuronide, taurocholate and DPDPE. The results clearly demonstrate that the three 
amino acid residues identified affected not only high affinity digoxin transport but also 
transport of substrates that are known as good substrates of Oatp1a1. Thus our 
prediction that using a chimera approach with digoxin to distinguish between 
Oatp1a1 and Oatp1a4 would allow us to identify amino acid residues that are 
important for overall Oatp1a4-mediated transport was confirmed. 
We do not know at the moment whether these amino acid residues are important for 
the three-dimensional structure of Oatp1a4 or are directly involved in substrate 
recognition. The bulkiness of the side chains e.g. in the amino acid residues 
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methionine at position 361 (M361) and phenylalanine at position 328 (F328) could be 
important to maintain the protein in a conformation optimal for high affinity substrate 
transport. Its loss would then lead to altered affinities as also suggested in an earlier 
chimeric analysis of the glucose transporters Hxt1 and Hxt2 in yeast [25]. That the 
changed amino acids rather change the overall conformation of Oatp1a4 and not 
directly interact with substrate binding is also supported by kinetic and inhibition 
studies performed with Oatp1a4 which suggest that estradiol-17-β-glucuronide 
interacts at a recognition site different from that for taurocholate and digoxin [6].  
Concomitant studies aiming at the generation of a theoretical structural model of 
representative OATP/SLCO superfamily members [26] emerged with some 
remarkable consideration concerning the location of the individual amino acids 
identified in our study. Analysis of the conservation pattern of representative OATPs 
identified the presence of a central pore that might be functionally significant. 
Measuring the electrostatic potential on the surface of the protein model showed that 
the putative pore was positive. This is consistent with a pore that is exposed to the 
aqueous phase and binding and transporting negatively charged compounds. The 
four sites F328V, S334, M361S and V354, face the pore in the theoretical models 
and may thus be expected to affect transport activity directly. Our findings with the 
oocytes expression system displayed affected transport efficiency after mutation for 
the former three sites as seen in Fig. 3. Moreover, A330G and V353A which have 
clearly no impact on transport efficiency, if mutated, are assumed to be buried in the 
models and are hence not expected to affect transport activity directly. 
In summary, we have identified three amino acids which are essential for Oatp1a4-
mediated transport. Mutations to the corresponding residue of Oatp1a1 decreased 
the apparent affinities for digoxin and DPDPE transport explaining the reduced 
transport rates. To further characterize and explain the underlying molecular 
mechanisms, additional experiments including crystallization of the substrate-
transporter complexes in combination with functional characterization of point 
mutations of critical residues are required. 
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5.1 Abstract 
Multispecific rat Oatp1a1 (Slco1a1) and the rat Na+/bile salt cotransporter Ntcp 
(Slc10a1) were expressed in Sf9 insect cells using the baculovirus expression 
system. Western blot analysis confirmed expression of the two transport proteins. Sf9 
cells infected with Oatp1a1 and Ntcp recombinant baculoviruses clearly exhibited 
substrate uptake, while wildtype-infected Sf9 cells did not accumulated any substrate 
investigated. Unexpectedly, Oatp1a1-mediated transport could not be confirmed with 
Oatp1a1 Sf9 membrane vesicles. An exterior pH 6, applying an inwardly directed H+-
gradient, did not stimulate estrone-3-sulfate uptake into Sf9 vesicles, although a pH-
dependent transport mechanism of Oatp1a1 has been proposed by other research 
groups. However, in Sf9 membrane vesicles isolated from Ntcp-expressing cells Ntcp 
successfully accumulated taurocholate in a sodium-dependent manner. Focus was 
therefore laid on the cotransporter Ntcp. Suitable conditions for direct solubilization 
were obtained with 0.4% of the detergent FOS-choline-16. Highest Ntcp-recovery 
turned out to be at ~ 1.8 mg protein of Ntcp Sf9 membrane vesicles per ml. 
Functional activity of solubilized Ntcp was proven with subsequent reconstitution into 
artificial liposomes. These proteoliposomes accumulated taurocholate sodium-
dependently in the same range as shown with Ntcp Sf9 membrane vesicles. It is 
therefore assumed that the conformation of Ntcp found in Sf9 membrane vesicles 
and after reconstitution is similar to conformation in intact liver cells. 
With these studies an expression system has been established which allows readily 
solubilization of functional Ntcp. For future isolation of purified Ntcp this system will 
enable analyses required to investigate the transport-competent protein structure of 
Ntcp. 
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5.2 Introduction  
Rat organic anion transporting polypeptide 1a1 (Oatp1a1, Slco1a1) and the 
Na+/taurocholate cotransporting polypeptide (Ntcp, Slc10a1) are both expressed in 
rat liver at the basolateral membrane of hepatocytes. Oatp1a1 is multispecific and 
mediates transmembrane transport of a wide range of endogenous and exogenous 
organic compounds (see also Introduction Chapter 1, Table 1). Ntcp, on the other 
hand, has much narrower substrate specificity. Principally Ntcp is responsible for 
transport of unconjugated and conjugated bile salts into hepatocytes [1].  
Knowledge about the transport mechanism of Oatp1a1-mediated transport is 
moderate. It is well established that Oatps/OATPs act in a sodium-independent 
manner and are capable of mediating anion exchange [2, 3]. Investigations with 
Oatp1a1 expressed in Xenopus laevis oocytes, in HeLa cells and in CHO cells 
suggested HCO3-, GSH or glutathione-S-conjugates as an anion being exchanged [4, 
5]. Different research groups pursued the investigation of the transport mode and 
suggested a pH-dependent transport mechanism [6, 7]. According to Satlin and co-
workers an inwardly directed H+-gradient stimulated taurocholate (TC) transport into 
HeLa cells expressing Oatp1a1 (pHi>pHo) [8]. Furthermore unpublished data from 
our laboratory suggest as well that Oatp/OATP-mediated uptake is either mediated 
with OH-- (HCO3-) exchange or H+-cotransport (see ETH PhD Thesis Nr.17208, 
Simone Leuthold). This hypothesis is based on investigations of Oatp1a1 and several 
other members of the OATP1 family upon the effect of the extra cellular pH on Oatp-
mediated substrate transport. With reference to transport mechanism Ntcp is well-
defined as a Na+/bile salt cotransporter. Thus driving force is an inwardly directed 
electrochemical Na+-gradient. This gradient is maintained by the basolateral Na+/K+-
ATPase as well as the negative intracellular potential [9, 10]. 
Most membrane transport proteins are present at low concentrations in their native 
tissue. Their overexpression is a requirement for direct solubilization and 
reconstitution. Sf9 cells are used as a high-level expression system and several 
mammalian membrane transport proteins have been successfully expressed and 
were functionally characterized in cells or in isolated membrane vesicles, amongst 
others rabbit Na+/Glucose cotransporter [11], rat renal Na+/Phosphate and 
Na+/Sulfate cotransporters [12] and several ATP binding cassette (ABC) transporters 
[13-15]. For our investigations Oatp1a1 and Ntcp were expressed in Sf9 cells using 
recombinant baculoviruses. 
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Solubilization is one of the first steps towards isolation of a membrane transport 
protein. Full isolation of a purified transport protein is a still prerequisite for 
characterization of structural properties and necessary for a complete molecular 
description of the function of transport-competent protein. The main problem 
associated with the functional isolation stems from the instability of the transport 
protein towards the harsh conditions during the processing for purification. Therefore 
the determination of the proper conditions for solubilization and reconstitution into an 
environment approximately the native membrane is an important first part of the 
strategy. Starting material originating from a high-yield expression system with large 
quantities is required. Effective solubilization of membrane proteins requires both, the 
selection of a detergent and appropriate solubilization conditions [16-18]. 
It is of capital importance that the detergent does affect neither secondary nor tertiary 
structure of the protein irreversibly, as this might impact functionality. Subsequent 
reconstitution enables measurement of functional activity. In case of membrane 
transport proteins the maintenance of functional activity can be conveniently followed 
by substrate transport into vesicles. As a reconstituted transporter is isolated in an 
artificial lipid bilayer, functional studies are easily possible. No complications from 
other membrane components occur, as it might be in a viable cell. To our knowledge 
rat Oatp1a1 and Ntcp have neither been isolated before from their natural lipidic 
environment nor from any heterologous expression system. 
With this study we pursued two objectives: The first aim was to establish standard 
methods for functional expression of Oatp1a1 and Ntcp in Sf9 cells. Secondly, we 
determined suitable conditions for direct solubilization of Ntcp Sf9 membrane 
vesicles with subsequent functional reconstitution into artificial liposomes. 
 
.
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5.3 Materials and Methods  
Materials I Radiolabelled [3H]-taurocholate (1.2 Ci/mmol) and [3H]-estrone-3-sulfate 
(57.3 Ci/mmol) were purchased from Perkin Elmer Life Sciences (Boston, MA, USA). 
The sodium salt of taurocholic acid and soya-bean asolectin were obtained from 
Fluka Chemie (Buchs, Switzerland). Cholesterol was from SIGMA (St.Louis, MO, 
USA) and the detergents used for solubilization were acquired as follows: n-octyl-β-
D-glucopyranoside (OG), n-dodecyl-β-D-maltopyranoside (DDM) and FOS-choline-16 
(FOS-16) from Anatrace (Maumee, OH, USA) and CHAPS from Applichem 
(Darmstadt, Germany). Cell culture media and reagents were purchased from 
Invitrogen (Groningen, The Netherlands) and BD Biosciences (Eremodegem, 
Belgium). Sf9 insect cells were obtained from BD Biosciences. All other chemicals 
were of the highest purity available from commercial sources. 
 
Expression of rat Ntcp and Oatp1a1 in Sf9 insect cells I Sf9 (Spodoptera 
frugiperda) insect cells were maintained in Grace’s insect cell culture medium 
supplemented with 10% foetal bovine serum (heat-inactivated) and 1 % 
penicillin/streptomycin and were grown as a monolayer culture in a humidified 
incubator at 27 °C. Recombinant wildtype (WT) baculovirus and baculoviruses 
carrying Ntcp and Oatp1a1 used for Sf9 cell infections had been generated in our 
laboratory prior to this study using the Bac-to-Bac® Baculovirus Expression System 
(Invitrogen) (data not shown). The viral titers were determined by serial dilutions, 
investigating its effect on the viability of Sf9 cells. A tetrazolium salt, MTT dye [19], 
was utilized giving a quantifiable colorimetric reaction assessing the virus’s effect in 
accordance with the virus titer. 
5 x 106 Sf9 cells per 10 cm dish or 55 x 106 Sf9 cells per 24.5 x 24.5 cm square plate 
were infected with recombinant viruses. Before adding the virus, Sf9 cells were 
routinely seeded and allowed to attach for one hour. Infections with WT control 
baculoviruses were performed at a multiplicity of infection (MOI) of 5, whereas 
infections with Ntcp baculoviruses were performed at a MOI of 20 and with the 
Oatp1a1 baculoviruses at a MOI of 7. Cells were harvested three days after 
infections and used for transport studies either in suspension or after the isolation of 
membrane vesicles. 
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Transport studies with Sf9 cells I To confirm the functionality of rat Ntcp and 
Oatp1a1 expressed in insect cells, transport studies with Sf9 cells in suspension 
were performed. 1 x 106 cells were washed twice with 1 ml Grace’s insect medium 
supplemented with 1 % penicillin/streptomycin, with centrifugation steps in between 
for 2 min at 1000 x g. Ntcp-expressing cells were then resuspended in 250 µl uptake 
buffer, which consisted of 5 mM D-glucose, 5 mM MgCl2, 3 mM CaCl2, 122 mM NaCl 
or CholineCl and 10 mM MES/Tris, pH 6.5 supplemented with 10 µM [3H]-
taurocholate. The uptake buffer for cells expressing Oatp1a1 consisted of 5 mM D-
glucose, 5 mM MgCl2, 3 mM CaCl2, 122 mM NaCl and 10 mM MES/Tris, pH 6.0 or 
10 mM HEPES/Tris, pH 7.5  supplemented with 10 µM [3H]-taurocholate or 0.5 µM 
[3H]-estrone-3-sulfate. Transport was allowed to take place for 15 min at 25°C and 
was then stopped by adding 1 ml uptake buffer containing 1 mM taurocholate and 
122 mM CholineCl. Cells were lysed with 1% Triton X-100 and the retained 
radioactivity determined by liquid scintillation counting (PerkinElmer Life Sciences, 
Boston, MA, USA). Protein concentrations were measured using the bicinchoninic 
acid (BCA) protein assay kit (Pierce, Rockford, IL, USA) [20]. 
 
Isolation of Sf9 membrane vesicles I Isolation of membrane vesicles from virus-
infected Sf9 cells was performed as described by Gerloff and co-workers [21]. In brief, 
Sf9 cells were scraped from culture dishes, centrifuged for 10 min at 1400 x g at 4°C 
and homogenized with 20 strokes with a glass-Teflon tissue homogenizer in 50 mM 
mannitol, 2 mM EGTA, 50 mM Tris/HCl, pH 7.0, 1 µg/ml leupeptin/antipain and 0.5 
mM phenylmethylsulfonyl fluoride. Undisrupted cells, nuclear debris, and large 
mitochondria were then pelleted at 500 x g for 10 min at 4°C. The supernatants were 
centrifuged for 1 hour at 100 000 x g. The resulting pellets containing membrane 
vesicles were resuspended by repeated syringing (20 times) through 25-gauge 
needles in 250 mM sucrose, 0.2 mM CaCl2, 20 mM HEPES/Tris, pH 7.5 for Ntcp Sf9 
vesicles. This medium had been prefiltered through 0.45 µm cellulose nitrate filters 
and will be referred to as SMS (standard membrane suspension buffer) throughout 
this chapter. For the Oatp1a1-expressing Sf9 vesicles the SMS consisted of 250 mM 
sucrose, 0.2 mM CaCl2, 100 mM NaCl and 20 mM HEPES/Tris, pH 7.5. Total protein 
concentrations were determined using the BCA protein assay kit. Vesicles were 
snap-frozen in liquid nitrogen and stored until required for transport studies. 
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Transport studies with Sf9 membrane vesicles I Transport into freshly thawed Sf9 
vesicles isolated from WT-infected, Ntcp- or Oatp1a1-expressing Sf9 cells was 
determined by a rapid filtration assay as described before [21, 22]. All solutions for 
the Ntcp Sf9 vesicle uptake were prepared with reference to transport studies with 
basolateral rat liver plasma membrane vesicles in Zimmerli et al [22]. For transport 
studies, Sf9 vesicle suspensions were diluted with SMS to the desired protein 
concentration (3.5 µg/µl) and Sf9 vesicles were then incubated at 37 °C in the uptake 
buffer. The latter had been prefiltered through 0.45 µm cellulose nitrate filters and 
consisted of 62.5 mM sucrose, 0.2 mM CaCl2, 6.25 mM MgCl2, 125 mM NaCl or KCl 
and 20 mM HEPES/Tris, pH 7.5 supplemented with 1 µM [3H]-taurocholate for Ntcp 
Sf9 vesicles. The uptake buffer for Oatp1a1 Sf9 vesicles contained 250 mM sucrose, 
0.2 mM CaCl2, 6.25 mM MgCl2, 100 mM NaCl and 50 mM MES/Tris, pH 6.0 and was 
supplemented with 0.5 µM [3H]-estrone-3-sulfate. Transport studies were carried out 
by adding 80 µl of the uptake buffer to 20 µl of vesicle suspension (70 µg 
protein/uptake), which had been preincubated in a tube at 37°C for 1 min. The tube 
was mixed vigorously and returned to a water bath for varying times. After the time 
periods indicated, uptake was terminated by addition of 3 ml ice-cold stop solution 
containing 100 mM sucrose, 5 mM MgCl2, 0.2 mM CaCl2, 100 mM KCl and 20mM 
HEPES/Tris, pH 7.5 for Ntcp Sf9 vesicles and 50 mM sucrose, 5 mM MgCl2, 0.2 mM 
CaCl2, 100 mM NaCl and 50 mM MES/Tris, pH 6.0, for Oatp1a1 Sf9 vesicles. 
Mixtures were vacuum-filtered rapidly through 0.45 µm cellulose nitrate filters 
(Sartorius AG, Goettingen, Germany), which had been pre-soaked in cold deionized 
water. In case of taurocholate transport studies the filters had been additionally 
rinsed with 2 ml of 1 mM unlabelled taurocholate, in order to reduce adherence of the 
bile acid to the filter. The test tubes were rinsed twice with additional 3 ml of the stop 
solution and the filter was then washed with a final 3 ml of stop solution. Vesicle-
associated radioactivity retained on the filters was determined by liquid scintillation 
counting. All Sf9 vesicle determinations were corrected for a 0-time-point at which 
addition of radio labelled substrate was followed immediately by 3 ml of ice-cold stop 
solution with subsequent washing-steps described above. Measurements were 
performed in triplicates and were confirmed with at least two separate membrane 
preparations.  
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Western blotting I Proteins in the Sf9 membrane vesicles (50-70 µg of total protein) 
or fractions of soluble and insoluble proteins were resolved by electrophoresis on an 
8 % (w/v) sodium dodecyl sulfate polyacrylamide gel. Protein samples were mixed 
with Lämmli’s sample buffer, with bromphenol blue as a tracking dye [23] and were 
then boiled for 1 min for complete denaturation. Following gel electrophoresis, 
proteins were transferred electrophoretically onto nitrocellulose membranes 
(Amersham Biosciences, Otelfingen, Switzerland) according to standard procedures 
[24]. After blocking hydrophobic and non-specific binding sites of the membranes 
with 5% milk (BIORAD, Reinach, Switzerland) diluted in Tris-buffered saline 
containing 0.2% Tween 20, the blots were probed with Ntcp and Oatp1a1 antibodies. 
The rabbit polyclonal Ntcp and Oatp1a1 antibodies raised against the C-terminal 
ends of Ntcp and Oatp1a1, had been previously generated in our laboratory [25, 26] 
and served as primary antibodies. Specificities of the Ntcp and Oatp1a1 antisera 
were tested with isolated basolateral rat liver plasma membranes [25, 27] (data not 
shown). The membranes were incubated for 2 hours with the Ntcp antibody at a 
dilution of 1:6000, while the Oatp1a1 antibody was at a 1:1000 dilution. Subsequently, 
the secondary antibody, a commercially available horse-radish peroxidase-
conjugated goat anti-rabbit antibody (Amersham Biosciences, Otelfingen, 
Switzerland), was used at a dilution of 1:30000. Bound antibodies were visualized 
with Uptilight HRP blotting chemiluminescent substrate (Interchim, Montluçon Cedex, 
France) and subsequent autoradiography on a KODAK image station 2000MM 
analyzer (Eastman Kodak Co., Rochester, NY, USA). 
 
Detergent solubilization of Ntcp Sf9 membrane vesicles and reconstitution of 
Ntcp in proteoliposomes I Solubilization of Sf9 vesicles was performed either in a 
final volume of 200 µl or for subsequent reconstitution experiments in a final volume 
of up to 7ml (≤ 30% of the void volume of the used gel filtration column, see below). 
Thus Sf9 vesicles were diluted with ice-cold solubilization buffer containing 100 mM 
KCl and 20 mM Tris/HCl, pH 7.5, supplemented with the respective detergents at the 
concentration indicated. Optimal solubilization conditions were determined as 
described in the results section. The solubilization reactions were vortexed several 
times during 1 hour incubation on ice. Insoluble material was collected as a pellet 
after centrifugation at 100 000 x g for 1 hour. The soluble and insoluble fractions 
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were assayed for protein concentrations; and in equal aliquots the presence of Ntcp 
was assessed by Western blot analysis using the Ntcp antiserum as described above. 
The clear supernatants will be referred to as the fraction of soluble proteins "Sol", 
while the fraction of insoluble proteins is abbreviated "Insol". 
Reconstitution was performed by reincorporation of the solubilized Ntcp into the lipid 
bilayer of liposomes, followed by rapid removal of the detergents using gel filtration. 
For this purpose 4 - 6 mg soya-bean asolectin with membrane stabilizing cholesterol 
(m/m ratio 9:1) [28, 29] was dissolved in diethylether and the samples were 
evaporated to dryness under a gentle stream of nitrogen gas. In order to ensure total 
removal of the organic solvent, the round bottom flask with lipids was vacuum dried 
for 1 hour. The thin film of lipids was dispersed with the clear solubilizate containing 
Ntcp, derived from the solubilization described above. The mixture was then allowed 
to form proteoliposomes with slight shaking for 1 hour at 4°C.  
Removing the FOS-choline-16 from the mixed micellar solutions was performed by 
gel filtration by means of a Sephadex G-50 (fine) column (1 x 30 cm, BIORAD, 
Reinach, Switzerland). The column was pre-equilibrated and eluted at a rate of 0.75 
ml/min with solubilization buffer. Fractions of 1.5 ml containing proteoliposomes were 
collected, as determined by turbidity measurements at 280nm, and pooled. The 
presence of Ntcp was confirmed by Western blotting. Proteoliposomes with 
incorporated Ntcp were then harvested by high-speed centrifugation at 290 000 x g 
for 1.5 hours. Recovered proteoliposomes were immediately resuspended in SMS, 
and homogenized by 20 passages through a 25-gauge needle. After protein 
determination with a BCA assay the proteoliposomes were kept on ice until used for 
taurocholate uptake by the rapid filtration assay. 
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Transport studies into proteoliposomes I In order to test functionality of the 
reconstituted Ntcp, uptake measurements into proteoliposomes was performed. 
These uptake measurements were carried out with reference to Sf9 membrane 
vesicles transport studies. Proteoliposome suspension was used in 20 µl aliquots 
(each containing 40-70µg protein) and mixed with 80 µl of Ntcp uptake buffer 
containing 125 mM NaCl or CholineCl and supplemented with 1µM or 10µM [3H]-
taurocholate. Timed uptake reactions were terminated with ice-cold stop solution as 
described before for transport studies with Sf9 membrane vesicles. Radioactivity 
associated with proteoliposomes was determined by liquid scintillation counting. All 
determinations were corrected for a 0-time-point. 
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5.4 Results  
Oatp1a1 expression and functional characterization in Sf9 insect cells I Prior to 
functional studies, recombinant baculovirus infection conditions were optimized, i.e. 
maximal Oatp1a1 expression with minimal MOI was investigated by Western blot 
analysis. Varying the MOI from 5 up to 15 revealed that expression did not 
accumulate past 7 MOI 3 days post-infection (data not shown). Thereafter we 
routinely infected Sf9 cells with Oatp1a1 baculovirus at a MOI of 7 pfu and harvested 
cells after 3 days. In Fig. 1 Sf9 cells infected with Oatp1a1 baculovirus were 
monitored by the use of a polyclonal antiserum [26] and showed expression of the 
protein. 70µg of total protein, the amount used for aliquots doing later transport 
studies with Sf9 membrane vesicles, was loaded onto the gel. As evident in Fig. 1 
proteins migrate as two broad bands at ∼ 80kD and at ~ 55kD, respectively. No 
bands are present in WT-infected control cells, when using the same Oatp1a1 
antiserum. Using isolated basolateral rat liver plasma membranes, mature N-
glycosilated Oatp1a1 migrates as one broad band at ~ 86 ± 6 kDa [26, 30].  
 
 
Fig. 1 
Expression of Oatp1a1 in baculovirus-infected Sf9 insect cells I Western blot analysis of 
membrane vesicles isolated from Oatp1a1-expressing and wildtype (WT)-infected Sf9 cells (70µg of 
protein/lane). Sf9 cells were infected with Oatp1a1 recombinant baculovirus at a MOI 7 and with 
control WT baculovirus at a MOI of 5, both for 3 days. Molecular weight markers are indicated in 
kilodaltons. 
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The Oatp1a1 protein synthesis in Sf9 cells has been clearly demonstrated. However, 
we wished to measure transport function in these cells. For this purpose two well-
established Oatp1a1 substrates were chosen: Estrone-3-sulfate (E3S) and the bile 
acid taurocholate (TC). Transport into Oatp1a1-expressing Sf9 cells was measured. 
In order to investigate a possible pH-gradient dependent transport mechanism we 
carried out Sf9 cell transport studies with an inwardly directed H+-gradient. E3S 
transport was investigated with external pH (pHo) 7.5 as well as with pHo 6.0. 
Oatp1a1-infected Sf9 cells, pHo 7.5, incorporated more than twofold more E3S than 
WT-infected Sf9 cells (Fig. 2). Acidification with pHo 6.0 increased E3S uptake even 
more during the whole time course. 
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Fig. 2 
Time course of estrone-3-sulfate transport into Oatp1a1-expressing Sf9 cells I Transport of [3H]-
estrone-3-sulfate (0.5 µmol/l) was determined 3 days after infection in Oatp1a1-expressing and WT-
infected cells at 25°C for 15 min. Uptake buffers were of pH 6.0 or 7.5. Data represent the means ± 
SD of triplicate determinations from at least two infections. 
 
 
The second substrate investigated showed the same phenomenon as found for E3S. 
As evident from the results in Fig. 3 taurocholate transport into Oatp1a1-expressing 
Sf9 cells is clearly higher than into WT-infected cells during the whole time course up 
to 30 min. This stimulation of TC transport can be associated with Oatp1a1. 
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Fig. 3 
Time course of taurocholate transport into Oatp1a1-expressing (●) and WT-infected (○) Sf9 
cells I Transport of [3H]-taurocholate (10 µmol/l) was determined 3 days after infection at 25°C for 15 
min in uptake buffer with pH 6.0. Data represent the means ± SD of triplicate determinations from at 
least two infections. Some variability is smaller than the symbols. 
 
 
Functional characterization of Oatp1a1 in Sf9 membrane vesicles I The uptake 
conditions from transport studies in Sf9 cells, namely the acidic pHo 6.0, were 
transferred to transport studies with Sf9 membrane vesicles isolated from Oatp1a1-
expressing Sf9 cells. Sf9 membrane vesicles allow the variability of pHi and pHo, a 
requirement for further studies on the pH-gradient as a possible driving force of 
Oatp1a1. The experiments with Oatp1a1 Sf9 vesicles with pHi/pHo 7.5/6.0 revealed 
unexpected results. E3S transport can not be associated with Oatp1a1 function. In 
Fig. 4 the time courses for E3S uptake look the same and are not distinguishable, 
whether Sf9 cells expressed Oatp1a1 or were infected with WT baculovirus.  
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Fig. 4 
Time course of estrone-3-sulfate transport into membrane vesicles isolated from Oatp1a1-
expressing (●) and WT-infected (○) Sf9 cells I Transport of [3H]-estrone-3-sulfate (0.5 µmol/L) was 
determined at pHi/pHo 6.0/7.5 as described in Material and Methods. Data represent the means ± SD 
of triplicate determinations of two separate membrane preparations. 
 
 
Ntcp expression and functional characterization in Sf9 insect cells I As 
described for Oatp1a1 baculovirus, routine infection was optimized beforehand, 
determining lowest MOI which leads to roughly constant Ntcp expression levels after 
3 days of infection. Infection was accomplished routinely at 20 MOI. Expression of 
the cotransporter Ntcp in Sf9 cells was first analyzed by immunoblotting. With the 
Ntcp antiserum proteins of approximately 30-35 kDa and ~55 kDa, respectively, were 
detected (Fig 5). Several weak bands were observed with WT-infected Sf9 cells, 
likely originating from Sf9 cell proteins, which are bound unspecifically by the 
polyclonal anti-Ntcp antibody.  
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Fig. 5 
Expression of Ntcp in baculovirus-infected Sf9 insect cells I Western blot analysis of membrane 
vesicles isolated from Ntcp-expressing and WT-infected Sf9 cells (70µg of protein/lane). Sf9 cells were 
infected with Ntcp recombinant baculovirus at a MOI of 20 and WT-infected Sf9 cells at a MOI 5, both 
for 3 days.  
 
 
In order to determine if Ntcp, when expressed in Sf9 cells, is functional, i.e. 
stimulates TC transport sodium-dependently, transport studies were carried out in 
Sf9 cells as well as in membrane vesicles isolated from Ntcp-expressing Sf9 cells. As 
illustrated in Fig. 6 Ntcp-expressing Sf9 cells exhibit a dramatically elevated level of 
TC.  In the presence of sodium TC uptake was stimulated 26-fold. Without sodium no 
TC was incorporated in the cells, as also seen in WT-infected control cells, 
suggesting no endogenous Na+-dependent TC transporter in Sf9 cells. 
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Fig. 6 
Ntcp expressed in Sf9 cells mediates taurocholate uptake in a sodium-dependent manner I 
Transport of [3H]-taurocholate (10µmol/l) was determined in Ntcp-expressing and WT-infected cells 3 
days after infection at 25°C for 15 min either in the presence (filled bars) or in the absence (open bars) 
of sodium. Data are given as the mean ± SE of triplicate determinations from one single infection. 
 
 
Functional characterization of Ntcp in Sf9 membrane vesicles I As illustrated in 
Fig. 7A, Ntcp Sf9 membrane vesicles demonstrate clearly higher TC uptake in the 
presence of sodium than in its absence; however, to a lower extent than first shown 
with Ntcp-expressing Sf9 cells. After reaching a peak, TC transport reverses slowly 
coming to equilibrium after 60 min. At this point, endogenous TC uptake in the 
absence of sodium and the TC uptake in the presence of sodium are at equilibrium 
across the vesicle membrane. The value is higher than the initial value but lower than 
the peak. In comparison vesicles of WT-infected Sf9 cells do not show a sodium-
dependent TC transport confirming the lack of an endogenous sodium-dependent TC 
transporter in Sf9 cells (Fig. 7B). 
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Taken together transport studies in cells and membrane vesicles displayed Ntcp 
functionality in the Sf9 expression system. Sf9 membrane vesicles with operating 
Na+/TC cotransporter were thereupon used as starting material for solubilization. 
 
 
 
 
Fig. 7 
Sodium-dependent time course of taurocholate transport into membrane vesicles isolated from 
Ntcp-expressing (A) and WT-infected (B) Sf9 cells I Transport of [3H]-taurocholate (1µmol/l) in the 
presence (●) and absence (○) of sodium was performed as described in the Material and Methods 
section. Data represent the means ± SE of triplicate determinations of two separate membrane 
preparations. The control experiment with WT-infected Sf9 vesicles was performed with three 
determinations of one membrane preparation. Some variability is smaller than the symbols. 
 
 
Detergent solubilization of Ntcp Sf9 membrane vesicles I Detergents are central 
to the isolation and solubilization of membrane proteins and the selection of a 
suitable detergent(s) is an important aspect of successful functional membrane 
solubilization and possible future purification. The choice of detergents was 
motivated by differences in head groups and hydrophobic regions. With the choice 
three main classes of detergents were covered. The non-ionic sugar-based 
detergents DDM and OG, the zwitterionic detergent CHAPS and FOS-choline-16, 
which is lipid-like, were used. Non-ionic detergents have been described as mild and 
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non-denaturing, but with short chains deactivation might occur. Zwitterionic 
detergents are generally more deactivating, for structural studies; however, they are 
commonly used [31]. 
After the provided functionality of Ntcp in Sf9 membrane vesicles the latter were used 
for direct solubilization. In order to compare the differences of each detergent, 
identical amounts of membrane vesicles were utilized. Complete and stable 
solubilization of membrane proteins generally occurs above the detergent critical 
micelle concentration (CMC). Here, we tested the solubilization of 2 mg of total 
membrane protein with the four detergents at concentrations specified in Table 1. 1% 
CHAPS was included in our studies with reference to Keller and co-workers, who 
used the zwitterionic detergent for solubilization and further purification of human 
OCT1 (SLC22A1) [32]. 
 
Table 1  
CMC and concentrations of detergents used for the solubilization of Ntcp Sf9 
membrane vesicles 
 CMC (w/v) concentrations used in % (w/v) 
 
FOS-16 
 
0.00053% 
80xCMC 
 
8xCMC 
0.4% 
 
0.04% 
 
DDM 
 
0.0087% 
 
80xCMC 
 
5xCMC 
0.7% 
 
0.04% 
 
OG 
 
0.53% 
15xCMC 
 
5xCMC 
8% 
 
2.5% 
 
CHAPS 
 
0.49% 
50xCMC 
 
2xCMC 
25% 
 
1% 
 
 
Solubilization was carried out as described in the Material and Method section. After 
high-speed centrifugation, the effectiveness of solubilization was analyzed in the 
supernatants. Using equal volumes of the supernatant (Sol) and of the fraction with 
insoluble proteins (Insol), Ntcp recovery was determined with Western blot analysis. 
Fig. 8 gives evidence for 0.4% FOS-16 (upper panel) and 8% OG (lower panel) being 
most effective in solubilizing Ntcp. For both detergents the fractions of soluble 
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proteins give clearly darker and bigger bands for Ntcp than found for the 
neighbouring lane loaded with the fractions of insoluble proteins. Solubilization with 
the other detergents demonstrated very similar bands for fractions of soluble and 
insoluble proteins or a weaker signal for Ntcp recovery in the supernatant. So, these 
results identified two candidate detergents for further characterization of Ntcp. 
However, further work with 8% OG for Ntcp solubilization revealed difficulties in its 
removal with subsequent gel filtration. Detergent originated foam was found in the 
collected fractions from gel filtration and was still visible after centrifugation to gain 
proteoliposomes. Incomplete Ntcp reconstitution possibly because of not tight 
proteoliposomes hindered transport studies (data not shown). 
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Fig. 8 
Solubilization of Ntcp Sf9 membrane vesicles with different detergents I 2 mg of total protein 
were solubilized as described in Material and Methods in the presence of the detergents indicated, 
each at concentrations described in Table 1. Identical aliquots of the supernatants with soluble 
proteins (Sol) and of the resuspended pellets with insoluble proteins (Insol) were probed for Ntcp by 
Western blotting. 
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Optimization of Ntcp solubility with FOS-Choline-16 I Further investigation with 
0.4% FOS-16 revealed an influence on detergent to membrane protein ratio on Ntcp 
recovery. An additional screen after solubilizing with 0.4% FOS-16 varying the 
amount of total protein of Ntcp Sf9 membrane vesicles was performed. Scanning 
results determining solubilities are shown in Fig. 9. When solubilizing 350 µg per 200 
µl, 0.4% FOS-16 dissolves Ntcp most, approximately 54% determined with scanning 
densiometry. With provided conditions only about 30% of total protein was extracted. 
After treatment with 0.4% FOS-16 the yield in solubilization of total protein was only 
20% for 600 µg and 15% for 850 µg of Ntcp Sf9 membrane vesicles. Consequently, 
further solubilization was carried out with 350 µg per 200µl, which comes to 1.8 mg of 
total protein of Ntcp vesicles per ml solubilization reaction. The resulting supernatant 
containing Ntcp was then subjected to reconstitution. 
 
Fig. 9  
Optimization of solubilization of Ntcp Sf9 membrane vesicles with 0.4% FOS-choline-16 at 
different detergent/membrane protein ratios I Total protein amount, indicated in µg, was solubilized 
in 200 µl as described in Material and Methods. Identical aliquots of the fractions with soluble and 
insoluble proteins were probed for Ntcp by Western blotting. The first lane was loaded with Ntcp Sf9 
membranes (50 µg of total protein). Scanning densiometry was performed on a KODAK Image station 
2000MM analyzer (Eastman Kodak Co., Rochester, NY, USA). 
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Sodium-dependent taurocholate transport into proteoliposomes containing 
Ntcp I Besides functional results Fig. 10A shows the assessment of Ntcp in different 
steps during solubilization and reconstitution of Ntcp with 0.4% FOS-16. Fraction #9 
is one of the fractions, which were proceeded with in the pool used for the last high-
speed centrifugation step to harvest proteoliposomes. On the other hand a late 
collected fraction (Fraction #32) was included in the analysis. Fraction #9, the pool 
#4-15 and prominently proteoliposomes are demonstrated to contain Ntcp as the 
immunoreactive pattern of Ntcp is identical to the pattern observed in Ntcp Sf9 
membrane vesicles. 
Functional studies with 1 µM TC, determined with the freshly resuspended pellet 
containing Ntcp proteoliposomes, are given in Fig 10B.  At both time points 
investigated sodium-dependent TC transport is demonstrated. After 5 min a 1.7- fold 
signal for TC uptake is found. At 10 min only 1.2-fold more TC is accumulated in the 
presence of sodium than in its absence. Adjusting the transport conditions to shorter 
time points and augmentation of TC concentration from 1µM to 10µM gave results 
shown in Fig. 11. The insert proves reconstituted Ntcp in the associated Western blot. 
Sodium-dependent TC uptake was just below 2-fold after 1 min.  
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Fig. 10 
Western blot analysis of fractions collected during solubilization and reconstitution of Ntcp (A) 
and sodium-dependent transport of taurocholate into proteoliposomes gained with gel 
filtration (B) I In (A) Ntcp and WT-infected Sf9 vesicles were used as controls at 50 µg of total protein 
per lane. Transport of [3H]-taurocholate (1 µmol/l) in the presence (filled bars) and absence (open 
bars) of sodium was performed as described in the Material and Methods section. Data represent the 
means ± SE  
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Fig. 11 
Sodium-dependent transport of taurocholate into proteoliposomes gained with gel filtration I 
Transport of [3H]-taurocholate (10 µmol/l) in the presence (filled bars) and absence (open bars) of 
sodium was performed as described in the Material and Methods section. Data represent the means ± 
SE. Insert shows Ntcp determined in proteoliposomes with Western blot analysis. 
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5.5 Discussion  
In the present study a high-level expression system for Oatp1a1 and Ntcp was 
established. Expression in Sf9 cells was suitable for transport studies with the two 
membrane transport proteins. Functional prove for Ntcp is obtained not only in Sf9 
cells but also in Sf9 membrane vesicles, secondly, suitable conditions were 
determined for direct solubilization of Ntcp. After solubilization with 0.4% (w/v) of the 
phospholipid analogue FOS-choline-16, initial attempts demonstrated that it is 
feasible to functionally reconstitute Ntcp into artificial liposomes.  
Both membrane transport proteins Oatp1a1 and Ntcp have been cloned and 
functionally expressed in Xenopus laevis oocytes and in mammalian cell lines [1, 2, 
26, 33]. However, they have not been expressed in a system from which they could 
be readily solubilized. The Sf9 insect cell line is as an expression system preferable 
to that of a prokaryote such as Escherichia coli because it is known that 
posttranslational modification of proteins is different in a bacterial system than in a 
eukaryotic expression system [34]. There is evidence that insect cells can perform 
most of the processing steps occurring in mammalian cells. As a consequence, there 
is a greater probability that a protein expressed in insect cells will have normal 
biological activity [35]. 
Expression of Oatp1a1 and Ntcp in Sf9 cells was monitored by Western blot. Results 
revealed that protein sizes determined (Fig. 1 and 5) diverge from published 
molecular weight of 86 kDa (Oatp1a1, [25, 26]) and 51 kDa (Ntcp, [25]) in isolated 
basolateral rat liver plasma membranes. Besides bands similar to published protein 
size, additional bands were detected at a lower molecular weight for both proteins. It 
can be speculated that the discrepancy between the molecular mass of the 
expressed Oatp1a1 and Ntcp and the mass observed in isolated basolateral rat liver 
plasma membranes might be explained by the lack of or by an incomplete 
glycosilation. Under-glycosilation in Sf9 cells has been shown for some transport 
proteins before. Many transport proteins have been, however, functionally expressed 
in Sf9 cells: Human and rat MRP1 (previously called MRP) were successfully 
investigated for substrate specificity in Sf9 cells, although shorter proteins were 
measured presumably due to lower degree of glycosilation [36]. Under-glycosilation 
of rabbit Na+/glucose cotransporter in Sf9 cells was described as well as not critical 
for function [11]. 
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Concerning Oatp1a1 one study investigated the functional role of N-glycosilation in X. 
laevis oocytes [30]. The results suggested that Oatp1a1 is dependent on N-
glycosilation as function is impaired when expressing Oatp1a1 in S. serevisiae, which 
has limited ability to carry out certain posttranslational modifications, including 
glycosilation. However, the precise role that glycosilation plays in the functional 
expression stayed unknown. Deglycosilation experiments done with Ntcp in isolated 
basolateral rat liver plasma membranes [25] decreased the molecular weight from 51 
to 33.5 kDa, which is in agreement with the lower bands found in our immunoblots. 
We do not know if glycosilation is incomplete or not. Since functional activity in Sf9 
cells for both transport proteins can be associated with the respective transporter (Fig. 
2, 3 and 6), it is suggested that the conformation of Oatp1a1 and Ntcp in Sf9 cells is 
similar to that in intact host tissue. 
Further functional characterization was carried out with transport studies using Sf9 
membrane vesicles expressing Oatp1a1 or Ntcp. An advantage of membrane 
vesicles to cells is methodically full access to intracellular and extra cellular 
conditions. Transport studies with pHi>pHo in Oatp1a1 Sf9 membrane vesicles were 
unexpected (Fig. 4). The inwardly directed H+-gradient did not activate E3S transport 
into vesicles, when comparing to endogenous E3S uptake into Sf9 membrane 
vesicles isolated from WT-infected cells. With this expression system we could not 
confirm in vesicles what was found in Oatp1a1-expressing HeLa cells, namely the 
H+-gradient as a possible driving force [8] of the transport protein. It is possible that 
after exterior acidification the H+-gradient was less sustainable with the buffer 
capacity of membrane vesicles than with viable cells.  
In contrast, the activity of Ntcp in Sf9 membrane vesicles could be shown. The 
Na+/TC cotransport is reflective for functional activity, known in hepatocytes (Fig. 7) 
and is reasonable in agreement with former studies carried out with isolated 
basolateral rat liver membrane vesicles. Within 1 min TC uptake was stimulated 3-5 
times [22], while Ntcp Sf9 membrane vesicles incorporated after the same time more 
than 2 times more TC in the presence of sodium than it its absence. In comparison 
this sodium-dependent signal is much lower than the signal found in Ntcp-expressing 
Sf9 cells. In Sf9 cells the accumulation was 26-fold in the presence of sodium. A 
possible explanation is altered orientation of the cotransporter after isolation of 
membrane vesicles. Moreover the lack of Na+/K+ ATPase after homogenizing and 
isolating membrane vesicles compared to fully functional cells might have an impact 
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on stability of the Na+-gradient applied. Former transport experiments with primary 
cultured rat hepatocytes [37] compared to studies with isolated basolateral rat liver 
membrane vesicles [22] displayed a 2-3-fold loss in sodium-dependent TC 
incorporation. This complies with the loss of TC uptake into Sf9 cells to TC uptake 
into Sf9 membrane vesicles, both expressing rat Ntcp. 
With sodium-dependent TC uptake into Ntcp Sf9 membrane vesicles functionality is 
provided. Solubilization conditions were established. Detergents from three main 
classes were used. In a first screen, moderate solubility of Ntcp excluded the sugar-
based detergent DDM and CHAPS, a zwitterionic surfactant, from further use (Fig. 8). 
Subsequent studies with the second sugar-based detergent OG revealed its 
impracticality. Removal of OG was incomplete after detergent dilution and 
subsequent gel filtration. Optimal solubilization conditions with 0.4% FOS-choline-16 
turned out to be at 1.8 mg protein of membrane vesicles/ml. 
In order to evidence solubilization of functionally active Ntcp, reconstitution into 
artificial liposomes was carried out promptly. Throughout solubilization and 
subsequent reconstitution Ntcp was monitored by Western blot analysis. The 
determined protein pattern of reconstituted Ntcp (Fig. 10A) was as shown before in 
Ntcp Sf9 membrane vesicles, implying neither degradation nor any harsh impact on 
the cotransporter during isolation. It was more crucial to demonstrate functionality. 
Since 1µM TC transport after 5 min was higher in the presence of sodium than in its 
absence, reconstituted Ntcp reveals functional activity. The signal at a later time point, 
namely 10 min, is moderate (Fig. 10B). 
Using our reconstitution system, the orientation in the proteoliposomes has not been 
defined. To overcome possible forfeit of outside-in Ntcp and in order to aim at a 
better TC signal, 10 times higher concentration of TC was used for uptake studies 
into proteoliposomes. 10µM is still below the published Km value for TC mediated by 
rat Ntcp. The Km has been consistently determined at 25 µM, in X. laevis oocytes 
[33], in hepatocytes [38] as well as in isolated basolateral rat liver plasma membrane 
vesicles [22]. After 1 min the highest sodium-dependent TC uptake was determined. 
This signal of reconstituted and functional active Ntcp is in the same range as was 
found for Ntcp Sf9 membrane vesicles. As it may be, it is the qualitative similarity 
between native Ntcp in Sf9 vesicles and reconstituted Ntcp transport properties 
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rather than the quantitative increase in specific transport activity that essentially 
proves transport function of Ntcp. 
 
The research presented provides results on functional expression and isolation of 
Ntcp from its lipidic environment using the baculovirus/Sf9 cell-based expression 
system. Furthermore Ntcp was reconstituted into an analogous milieu that mimics the 
lipid bilayer; where Na+/ TC cotransport was proven.  
This system will be useful for future studies aimed at structural determinations. The 
method of reconstitution will serve for purification and will be of use to monitor the 
transport activity of Ntcp during each step of purification. Future isolation of purified 
Ntcp will enable analyses required to investigate the transport-active form of Ntcp. In 
case of clarity upon driving force(s) of Oatps/OATPs these procedures established 
should be useful for isolating members of the OATP superfamily. 
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General Discussion and Perspectives 
 
 
CHAPTER 6 I General Discussion and Perspectives 
Studies with individual members of the OATP superfamily have concentrated on 
aspects of their multispecificity, i.e. the apparent affinity constants (Km) and cis-
inhibition pattern of different endogenous and exogenous substrates. The remarkably 
extensive work done with OATP1 family members led to the investigations in line with 
this PhD thesis. Functional determinants for transport activity of members of the 
OATP1 family have been outlined. 
 
In our first study we examined an evolutionarily ancient Oatp found in skate liver, 
Oatp1d1 [1]. It was of interest to examine whether Oatp1d1 as an evolutionary 
precursor shares transport of the toxins phalloidin and microcystin with mammalian 
liver Oatps/OATPs. Oatp1d1 indeed mirrors the toxin transport properties of the more 
evolved mammalian Oatps/OATPs. The closest mammalian Oatp1d1 orthologue 
OATP1C1 did not share the phalloidin transport activity. The two transporting 
polypeptides exhibit only 50.4% amino acid sequence identity, which in this case is 
assumed to be not sufficient for comparable substrate specificity. 
It remains to be investigated also with closer related orthologs and/or paralogs 
whether there are evolutionarily conserved structural determinants that account for 
overlapping substrate profiles. Meier-Abt et al identified novel Oatps in other 
evolutionarily ancient animals with database search [2]. Oatps have been identified in 
zebra fish, frog, fruit fly and worm; all these animals are in representative positions in 
animal evolution and their genomes have been fully sequenced. In assumption of 
their future expression cloning, these less evolved Oatps could be used in 
comparative functional genomic studies with well-investigated more evolved 
Oatps/OATPs. 
In connection with the characterization of Oatp1d1 two aspects of importance for 
future functional characterization of Oatps/OATPs have to be addressed: In this first 
study inhibition studies with common Oatp/OATP-substrates were carried out with 
isolated skate hepatocytes expressing Oatp1d1. Such experiments address the great 
interest in specific inhibitors for transport proteins such as Oatps/OATPs. Screening 
experiments on a large scale would possibly succeed in identification of specific 
inhibitors. Such specific inhibitors would ease matters for further more detailed 
functional characterization in cells where multiple Oatps/OATPs are expressed. 
Moreover, such inhibitors could be developed into drugs to treat toxin-induced liver 
injury.  
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The second aspect addresses substrates ideal for functional characterization. Other 
exogenous or endogenous compounds of the multispecific Oatps/OATPs than toxins 
would be preferable for possible future comparative transport studies. Research work 
with the toxins such as microcystin used as a substrate turned out not to be very 
practical, as they are toxic for amphibian and mammalian cells required for transport 
studies. As many Oatps/OATPs are found to be low affinity toxin transporters, see 
Table below (for references see Introduction Chapter 1, Table 1), it is necessary to 
work with higher concentrations, which in turn leads to severe cytotoxic effects.  
Either way Oatp/OATP-mediated toxin transport could be demonstrated for various 
members of the OATP1 family. Substrate specificity includes ochratoxin A, α-
amanitin, phalloidin and microcystin. 
 
Apparent affinity for toxins of OATP1 family members 
Oatp/OATP Toxin Km [µM] 
Oatp1a1 Ochratoxin A 17-29 
OATP1A2 Microcystin 20 
Oatp1a3 Ochratoxin A 6-17 
Oatp1B1 Microcystin 
Phalloidin 
7 
17-39 
Oatp1b2 Microcystin 6 
Oatp1B1 Microcystin 
Phalloidin 
α-Amanitin 
4 
8 
9 
 
 
The fact that OATP1 family members transport several toxins suggest a certain 
physiological role, namely their involvement in elimination and detoxification 
processes in the tissues where they are expressed.  
 
The interest for more comparative functional genomics in assessing important 
structural determinants among the OATP superfamily underlies the second study. In 
comparison to skate Oatp1d1 and human OATP1C1 with 50.4% amino acid 
sequence identity, the two rat paralogs, Oatp1a4 and Oatp1a1, exhibit more than 
77% amino acid sequence identity. They clearly show different substrate specificity 
regarding digoxin transport. On this basis chimeric constructs and single Oatp1a4 
mutants were generated. Three amino acids were identified in Oatp1a4 with this 
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approach. When mutated to amino acids of Oatp1a1, digoxin and overall Oatp1a4-
mediated transport properties were affected. Kinetics for Digoxin and DPDPE 
investigated was altered with decreased apparent affinities (Km). The underlying 
mechanism for these results remains unclear. We do not know whether the 
conformation of the transporting polypeptide changed or whether the amino acids are 
directly involved in substrate binding. The theoretical model of human OATP1B3 as 
generated by Meier-Abt and co-workers [2] bears novel questions. Some conserved 
amino acid residues have been postulated to be exposed to the pore (i.e. solvent-
exposed and responsible for the positive potential) others to be buried in the model. 
Moreover, conserved amino acids have been identified as being involved in 
hydrogen-bonds conserved throughout the OATP1 family. And several amino acid 
residues were localized in the theoretical model in positions necessary for breaks 
and bends of the TMHs. Taken together site-directed mutagenesis and functional 
characterization of the residues in question would provide further information on the 
exact role of these amino acid residues. As a theoretical model was generated with 
human OATP1B3, the track could be followed with this human liver OATP. Of course, 
a chimera approach would be applicable onto other closely related Oatps/OATPs 
which exhibit differences in substrate specificity.  
 
For complete molecular description of function and of the transport mechanism(s) 
further work is necessary. Functional experiments with site-directed mutagenesis of 
critical residues are one approach. On the other hand, functional isolation of the 
purified transport protein would enable biophysical studies, e.g. to determine the 
oligomeric state, and would be a first step towards determining protein structure. 
Initial work towards the isolation of a membrane transport protein were carried out in 
our third investigation with Oatp1a1 and Ntcp. The initial knowledge with reference to 
transport mechanism for Oatp1a1 and Ntcp was, however, not comparable. 
Transport mode of Oatps/OATPs has not been fully described. Using the 
baculovirus/Sf9-cell based expression system a possible pH-gradient dependent 
transport mode of Oatp1a1 was pursued. Studies with Oatp1a1 Sf9 membrane 
vesicles, however, were without success, because measured transport was not 
different from WT Sf9 membrane vesicles. We included Ntcp in this study, as the 
transport mode is clearly described as a Na+/bile salt cotransport. With the 
established expression system it was feasible to determine optimal solubilization 
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conditions for functional Ntcp. Further reconstitution into artificial liposomes enabled 
proves of the transport-competent conformation of Ntcp. 
So, first steps were undertaken for isolation of a mammalian membrane transport 
protein. A necessity for subsequent steps would be scaling up the amount of 
solubilized Ntcp. Crystallization requires pure protein in the range of mg amounts. 
After direct solubilization of Ntcp-expressing Sf9 membrane vesicles pure protein 
could be obtained with a high affinity ideally monoclonal antibody. Otherwise tagged 
Ntcp-constructs, e.g. His-tagged Ntcp, would facilitate later purification with metal-
affinity chromatography.  
 
Despite the novel insights into structure-function relationship of Oatps/OATPs 
outlined above, there are still open questions in relation to more complete 
understanding of Oatps/OATPs.  
Firstly, with reference to the role of membrane transport proteins in drug disposition 
the functional and physiological importance of Oatps/OATPs is still to be described in 
more detail. Investigations should include profound determination of tissue 
distribution and detailed functional characterization. A big aid would be the 
determination of specific Oatps/OATPs inhibitors. Taken together this might lead to 
understanding the clinical importance of Oatp/OATPs. 
Secondly, concerning the molecular description of Oatps/OATPs knowledge is still 
scarce. The detailed 3D-structure of Oatps/OATPs is not solved up to date. 
Crystallographic structure determinations of mammalian membrane proteins are rare 
and difficult to obtain. Several procedures are available, though. They allow at least 
partial prediction of the protein structure. These methods include computational 
analysis or NMR investigations of soluble domains of Oatps/OATPs. In addition, 
aggregates and clusters, which are formed in the plasma membrane with 
Oatps/OATPs are highly overexpressed in mammalian cells, could help to clarify the 
protein structure using electron microscopy or 2D crystallography. 
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